



## NIH PUBLIC ACCESS

## Author Manuscript

*Mutat Res.* Author manuscript; available in PMC 2010 August 2.

Published in final edited form as:

*Mutat Res.* 2009 August 2; 678(2): 76–94. doi:10.1016/j.mrgentox.2009.05.006.

## The Formation and Biological Significance of *N7*-Guanine

### Adducts

Gunnar Boysen<sup>1,2,\*</sup>, Brian F. Pachkowski<sup>2</sup>, Jun Nakamura<sup>2</sup>, and James A Swenberg<sup>2,\*</sup><sup>1</sup>Department of Environmental and Occupational Health, The University of Arkansas for Medical Science, Little Rock, AR<sup>2</sup>Department of Environmental Sciences and Engineering, The University of North Carolina, Chapel Hill, NC

### Abstract

DNA alkylation or adduct formation occurs at nucleophilic sites in DNA, mainly the *N7*-position of guanine. Ever since identification of the first *N7*-guanine adduct, several hundred studies on DNA adducts have been reported. Major issues addressed include the relationships between *N7*-guanine adducts and exposure, mutagenesis, and other biological endpoints. It became quickly apparent that *N7*-guanine adducts are frequently formed, but may have minimal biological relevance, since they are chemically unstable and do not participate in Watson Crick base pairing. However, *N7*-guanine adducts have been shown to be excellent biomarkers for internal exposure to direct acting and metabolically activated carcinogens. Questions arise, however, regarding the biological significance for *N7*-guanine adducts that are readily formed, do not persist, and are not likely to be mutagenic. Thus, we set out to review the current literature to evaluate their formation and the mechanistic evidence for the involvement of *N7*-guanine adducts in mutagenesis or other biological processes. It was concluded that there is insufficient evidence that *N7*-guanine adducts can be used beyond confirmation of exposure to the target tissue and demonstration of the molecular dose. There is little to no evidence that *N7*-guanine adducts or their depurination product, apurinic sites, are the cause of mutations in cells and tissues, since increases in AP sites have not been shown unless toxicity is extant. However, more research is needed to define the extent of chemical depurination versus removal by DNA repair proteins. Interestingly, *N7*-guanine adducts are clearly present as endogenous background adducts and the endogenous background amounts appear to increase with age. Furthermore, the *N7*-guanine adducts have been shown to convert to ring opened lesions (FAPy), which are much more persistent and have higher mutagenic potency. Studies in humans are limited

\* Corresponding authors: James A. Swenberg DVM, PhD, University of North Carolina at Chapel Hill, Department of Environmental Sciences and Engineering, 253 Rosenau Hall, Chapel Hill, NC, 275199, james\_swenberg@unc.edu, Gunnar Boysen, PhD, University of Arkansas Medical Sciences, Department of Environmental and Occupational Health, 4301 West Markham St., Slot 820, Little Rock, AR 72205, gboysen@uams.edu.

Supplemental Information: The supplemental tables are provided in Microsoft Excel format to allow sorting and incorporation into a database for searching if needed. These tables were the basis for our review. Given the numbers of publications, we are certain that this compilation will not be complete and apologize for any references that were not included. All values are given as adducts /10<sup>7</sup> normal nucleotides (nnt). In case other units were reported, values were converted as followed;

I. pmol adduct/  $\mu\text{mol Gua} = 1.95 \text{ adducts}/10^7 \text{ nnt}$

II. fmol/  $\mu\text{g DNA} = 3.25 \text{ adducts}/10^7 \text{ nnt}$

If data were reported graphically, values were estimated from figures. These values need to be used with some caution, as they do not represent exact values.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

in sample size and differences between controls and study groups are small. Future investigations should involve human studies with larger numbers of individuals and analysis should include the corresponding ring opened FAPy derivatives.

## Keywords

*N*7-guanine adducts; mutagenesis; biomarkers; exposure assessment; Dose-response

## 1 Introduction

DNA alkylation or adduct formation occurs at nucleophilic sites in DNA. Of these nucleophilic sites, the *N*7-position of guanine is the most reactive [1]. A PubMed search on “*N*7-guanine adducts” resulted in over 300 publications with 9 out of 10 focusing on basic characterization of chemical or biochemical properties of *N*7-guanine adducts alone or in DNA. In addition, *N*7-guanine adducts are classified as non promutagenic since they are chemically unstable and the *N*7-position does not participate in Watson Crick base pairing [2]. Ever since identification of the first *N*7-guanine adduct [1], several hundred studies on DNA adducts have been reported and reviewed from different perspectives [3-16]. Consequently, many studies sought to establish the relationship between DNA adduct formation and other biological endpoints (mutations, DNA strand breaks, *etc.*). Technical limitations, however, did not permit integration into large molecular epidemiological studies during this era of lesion characterization. Despite superior sensitivity of the <sup>32</sup>P-postlabeling assay, insufficient chemical specificity made it impossible to identify the chemical source of damage, and chemical depurination of *N*7-guanine adducts during sample preparation was a major concern. Almost all studies started with *in vitro* proof of concept experiments demonstrating covalent binding of the compounds of interest or their metabolites to DNA. Surprisingly, the identification and development of sensitive analytical methods remain a primary focus of many DNA adduct studies, even 50+ years later.

*N*7-guanine adducts appear to be good biomarkers of internal exposure because of their higher abundance compared to other DNA alkylations. Questions arise, however, regarding the biological significance for *N*7-guanine adducts that are readily formed, do not persist, and are not likely to be mutagenic. Thus, we set out to review the current literature to evaluate their formation and the mechanistic evidence for the involvement of *N*7-guanine adducts in mutagenesis or other biological processes.

### 1.1 Formation of DNA adducts

Miller and Miller pioneered the field of chemical carcinogens and were the first to demonstrate covalent binding of chemical carcinogens to macromolecules *in vivo* [17,18]. The first evidence for binding of chemical carcinogens or their metabolites to nucleic acid was reported by Wheeler and Skipper [19]. It quickly became apparent that carcinogens comprise a diverse group of chemicals. Some of them were from endogenous sources or natural products, while others arise from synthetic products of modern human life. These chemicals are able to react with nucleophilic sites (electron rich, S, N, and O), in DNA and proteins. Subsequent *in vitro* and *in vivo* studies quickly demonstrated that under physiological conditions (pH 7.4, 37° C), alkylation of DNA primarily occurred at the *N*7-position of guanine (Table 1) [20]. The distribution of methylation and ethylation adducts in DNA was studied in *in vitro* reactions, in bacterial or mammalian cell cultures, and in several tissues of mice and rats (reviewed by Beranek [8]). Overall, it confirmed the notion that the relative distribution of alkylation in DNA is similar *in vivo* and *in vitro* [21]. However, as technology advanced and allowed examination of lower exposures distinct differences in adduct distribution were established (see Section 2).

Binding was shown to mainly occur *via* monomolecular ( $S_N1$ , *e.g.*, nitrogen mustards) or bimolecular nucleophilic ( $S_N2$ , *e.g.*, sulfonyl esters) substitutions [22-24].  $S_N2$  reactions are heavily dependent on steric accessibility while  $S_N1$  reactions generally follow first-order kinetics. In DNA, the ring nitrogens and the exocyclic oxygens are the preferred sites for alkylation. Although the *N7*-position is the major site of alkylation, the electrophilic species formed by the *N*-nitroso compounds for example, following  $S_N1$  kinetics, will have a greater preference for reaction at the exocyclic oxygens than will the alkanesulfonates, which are limited to  $S_N2$  reactions. The larger the alkyl group is, the stronger will be its preference for reaction at the  $O^6$ -position of guanine. Hence, *N*-ethyl-*N*-nitrosourea (ENU) binds more efficiently to the  $O^6$ -position than does *N*-methyl-*N*-nitrosourea (MNU) (Table 1)[8,25,26]. The important difference in alkylation agents undergoing  $S_N1$  or  $S_N2$  reactions is that agents capable of  $S_N1$  reactions react more frequently at the  $O^6$ -position of guanine, thus producing more mutagenic  $O^6$ -guanine adducts, compared to agents that solely react *via* the  $S_N2$  mechanism.

These early binding experiments in DNA, cell culture and animal studies also showed that some carcinogens required metabolic activation to gain their ability to form DNA adducts and to exhibit their mutagenic and carcinogenic effects. Consequently, compounds were classified as “direct-acting” or “metabolically activated” carcinogens. The latter type is also termed a pro-carcinogen. In addition to mono adducts, compounds with multiple reactive groups were shown to have the ability to form protein-protein, DNA-DNA or protein-DNA cross-links [20]. The decades following have produced a better understanding of the relationship between carcinogen exposures, DNA adduct formation, mutagenesis, and carcinogenesis [4-7,10,12, 27]. Various technologies have been applied to animal and human exposure studies for routine analysis of *N7*-guanine adducts and other DNA adducts. These studies have increased our understanding of formation and persistence of DNA adducts, and their relationship to carcinogenesis. It has become clear that cancer is a complex, multi-step process that varies with types of exposure, site of tumor induction, and species. Understanding the implications of *N7*-guanine adducts has significantly contributed to identification of the mode of action in chemically-induced mutagenesis and carcinogenesis. These findings have subsequently led to a better understanding of the role of DNA adducts in mutagenesis and mechanism-based risk assessment [27].

## 1.2 Stability of *N7*-guanine adducts

Compared to many other DNA adducts, *N7*-guanine adducts are chemically unstable, with half lives in double-stranded DNA (dsDNA) ranging from as little as 2 h to 150 h. The instability of *N7*-guanine adducts is created by the formal placement of an additional positive charge on the guanine ring system. In general, larger alkyl groups promote depurination in dsDNA. This has been demonstrated under physiological conditions (pH 7.4, 37°C), where the half-lives for *N7*-methyl-guanine (*N7*-Me-Gua), *N7*-(2-hydroxy-3-butene)-guanine (*N7*-HB-Gua) and *N7*-(trihydroxy-benzo[*a*]pyrenyl) guanine are 150 h, 50 h, and 3 h, respectively [28-31]. In addition, *N7*-guanine adducts accumulate in DNA with continuous exposure or treatment and usually reach a plateau (steady state) after ~7-10 days [15,32-34]. Steady state is reached when the rate of *N7*-guanine adducts formed is equal to the rate of adducts lost. In contrast, adducts that are more persistent, such as  $O^4$ -ethyl-thymidine ( $O^4$ -Et-Thy), accumulate over a period of 4 weeks [35], and  $O^6$ -methyl-guanine ( $O^6$ -Me-Gua) in the brain continue to accumulate over 6 weeks of dosing [36]. The formal placement of an additional positive charge on the guanine ring system also promotes further reactions that have been reviewed by Gates *et al.* [37]. Relative to guanine, *N7*-Me-Gua depurinates  $10^6$  times more rapidly at pH7, 37 °C [37]. Reactions characteristic for *N7*-guanine adducts are: (i) loss of C-8 proton, (ii) depurination, (iii) ring opening to yield 5-*N*-alkyl-2,6,-diamino-4-hydroxyformamidopyrimidine (alkyl-FAPy), (iv) hydrolysis of the *N7*-alkyl bond, and (v) rearrangement to C8 adducts. For details

of the chemical reactivity of N7-guanine adducts, the reader is referred to the thorough review by Gates [37].

### 1.3 Methods for detection of N7-guanine adducts

During the past 50 years many technologies have been used for analysis of N7-guanine adducts. These technologies have been applied to rodent and human exposure studies for routine analysis of N7-guanine adducts and other DNA adducts. In the earliest studies, radiolabeled carcinogens were administered to rodents and binding to protein, RNA, and DNA was assessed by scintillation counting of the corresponding cellular fractions [38]. After DNA isolation and hydrolytic treatments, individual DNA adducts could be purified and quantified by basic column chromatography. This approach allowed analysis of one sample per day, with a detection limit of 1 adduct per  $10^6$  normal nucleotides (nnt) using  $\geq 5$  mg DNA [29,39]. Longer exposure regimes were laborious and expensive, due to the requirement of radiolabeled carcinogen for these studies. Consequently, most studies employed single exposures [40,41].

By the 1980's, HPLC with fluorescence detection, radioimmunoassay, or enzyme-linked immuno sorbent assay were commonly used for the analysis of DNA adducts. These approaches significantly increased throughput, reduced cost *via* elimination of custom radioisotope synthesis, and allowed application to study designs that included multiple exposure protocols. The extended exposure protocols provided information on the steady-state concentrations of DNA adducts and demonstrated that what had previously appeared to be minor adducts following single exposures could actually become major adducts if they were poorly repaired and accumulated with extended exposure [42]. These methods, however, had limited sensitivity compared to present day technology and some of the immunoassays were prone to false positive results due to cross-reactivity.

A major break through in methodology occurred in 1982, when Randerath and colleagues developed  $^{32}\text{P}$ -postlabeling methods for DNA adducts [43]. The limit of detection for the early  $^{32}\text{P}$ -postlabeling assays was 1 adduct per  $10^8$  nnt using as little as 1-2  $\mu\text{g}$  DNA [43,44]. Subsequently, combinations of  $^{32}\text{P}$ -postlabeling with HPLC or immunoaffinity permitted larger amounts of DNA to be analyzed and improved the sensitivity by one or more orders of magnitude. The major problems associated with this methodology include the lack of chemical-specific identity and poor reproducibility [45,46]. The  $^{32}\text{P}$ -postlabeling method was most suitable for more stable DNA adducts, such as etheno adducts [47-49] and N<sup>2</sup>-guanine adducts derived from polycyclic aromatic hydrocarbons (PAH) [50], and less so for N7-guanine adducts, due to their instability.

More recently, advances in mass spectrometry have lowered the limit of detection for this chemical-specific and quantitative technology, making it the method of choice in contemporary investigations. Earlier studies applied gas chromatography - negative ion chemical ionization - mass spectrometry (GC-MS), after hydrolysis and derivatization, to the analysis of DNA adducts [51-56]. Presently, however, the vast majority of quantitative analysis of DNA adducts is performed with liquid chromatography tandem mass spectrometry (LC-MS/MS). The application of mass spectrometry for DNA adducts has been recently reviewed by Singh and Farmer [57] and others [15,16,58-63]. Major advances in instrumentation for both mass spectrometry and chromatography have increased the detection limits for DNA adducts up to 100-fold, making it possible to routinely measure 1 adduct per  $10^8$  nnt. A major advantage of GC- and LC-MS/MS methods is the utilization of chemically identical stable isotope labeled internal standards for accurate quantitation.

The greatest sensitivity for measuring DNA adducts, however, is achieved with accelerator mass spectrometry (AMS), which can quantitate down to 3 adduct per  $10^{11}$  nucleosides using 1  $\mu\text{g}$  DNA [64]. While this method is extremely sensitive, it is limited to the following

radioisotopes ( $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{26}\text{Al}$ ,  $^{41}\text{Ca}$ ,  $^{10}\text{Be}$ ,  $^{36}\text{Cl}$ ,  $^{59}\text{Ni}$ ,  $^{63}\text{Ni}$ , and  $^{129}\text{I}$ ), of which  $^{14}\text{C}$  and  $^3\text{H}$  are the most commonly used in biomedical research. Therefore, specific chemical syntheses are required to either obtain radioisotope-labeled test compounds or for chemical labeling of compounds of interest (postlabeling, derivatization). Unfortunately, access to AMS is limited worldwide (only 5 instruments as of 2007), mainly due to the expense of the mostly custom-made instruments [65].

## 2 Formation of *N7*-guanine adducts in animal models

Several investigators have successfully utilized *N7*-guanine adducts as biomarkers to answer important toxicology questions in rodent models. These studies used multi-dose exposure protocols to generate comprehensive dose-response curves. Data from studies in mice and rats are presented in supplemental materials (Table S1 and Table S2). Adduct formation was compared to other biological endpoints such as unscheduled DNA synthesis, mutation frequency, micronucleus, apurinic sites (AP sites), gene expression, and others [7, 10, 12, 66]. In the following sections we will describe studies demonstrating factors influencing the formation and persistence of *N7*-guanine adducts. First, metabolic activation and subsequent formation of *N7*-guanine adducts can be species, strain, tissue, and cell dependant [32, 67-69]. Second, chemical stability and DNA repair influence the ratios of *N7*-guanine adducts to other DNA adducts [36, 40]. Lastly, there is some evidence for accumulation and increased tolerance to, and higher formation rates of *N7*-guanine adducts in DNA at later ages compared to young ages [70, 71].

### 2.1 Nitrosourea compounds

*N*-methyl-*N*-nitrosourea (MNU) primarily induced tumors in the nervous system in rats and lymphoid tumors in mice [72-74]. Subsequent analysis of *N7*-Me-Gua in several tissues of MNU-treated A/J and C3H3B/FeJ mice showed the highest formation of *N7*-Me-Gua and *O*<sup>6</sup>-methyl-guanine (*O*<sup>6</sup>-Me-Gua) in liver, kidney, lung, and brain, suggesting that adduct formation might be involved in carcinogenesis (Figure 1) [75]. Comparison of the ratio of *N7*-guanine adducts to *O*<sup>6</sup>-guanine adducts in brain and liver, assuming no active repair for *N7*-Me-Gua, suggested somewhat slower repair of *O*<sup>6</sup>-Me-Gua in the more susceptible C3H3B/FeJ strain than in A/J mice [75]. Persistence of *N7*-Me-Gua was similar in liver (non-target tissue) and brain (target tissue), suggesting that *N7*-Me-Gua adducts are most likely not causally linked to mutagenesis and carcinogenesis. *O*<sup>6</sup>-Me-Gua adducts, however, were removed much faster in liver than in brain, demonstrating active removal in the liver and suggesting involvement of *O*<sup>6</sup>-Me-Gua in mutagenesis and carcinogenesis [76]. In contrast, the persistence and amounts of *O*<sup>6</sup>-Me-Gua were similar in brain of both rats and mice, although these species differ markedly in their susceptibility to brain tumorigenesis, with the rat being a much more susceptible species [73,77]. It was concluded that organotropic carcinogenic effects of methylating carcinogens do not solely depend on DNA adduct formation and persistence, since formation and persistence correlated only in certain cases with tumor formation [75,78,79].

From the earliest studies on *N7*-guanine adducts, it quickly became apparent that certain adducts exist in control DNA and the notion of endogenous DNA damage was established. Amounts of *N7*-Me-Gua were 2-fold higher in liver DNA of rats that were 24 months old compared to 6 month-old animals, suggesting accumulation with age [71]. Similarly, endogenous amounts of *N7*-Me-Gua were twice as high in 29 month-old C57BL/6NNia mice, compared to 11 month-old mice [70]. More importantly, not only was the endogenous amount higher in older mice (29 month), they also formed twice as many *N7*-Me-Gua adducts as younger mice after 25 or 50 mg/kg MNU-treatment (11 months) [70]. These two reports demonstrate that endogenous background amounts and adduct formation may be significantly different at different ages. Unfortunately, to our knowledge age dependence of *N7*-guanine adduct formation has not been systematically investigated. Future studies should include

establishing endogenous background amounts of *N7*-guanine adducts and their formation in target tissues at different ages in mice, rats, and humans.

*N*-Ethyl-*N*-nitrosourea (ENU), similar to MNU, is a potent carcinogen inducing mainly tumors of nervous system and forming *N7*-ethyl-guanine (*N7*-Et-Gua) and *O*<sup>6</sup>-ethyl-guanine (*O*<sup>6</sup>-Et-Gua) adducts. The persistence of *N7*-Et-Gua adducts is dependent upon their chemical stability and possible elimination by active DNA repair enzymes. It has been shown that DNA repair capacity is tissue-specific and influences accumulation of promutagenic *O*<sup>6</sup>-Et-Gua, *O*<sup>4</sup>-Et-Thy and *O*<sup>2</sup>-ethyl-thymidine (*O*<sup>2</sup>-Et-Thy) adducts, but not *N7*-Et-Gua adducts [40]. Tissue-specific DNA repair can greatly affect dose-response of DNA adducts as exemplified with *O*<sup>6</sup>-Me-Gua and *O*<sup>6</sup>-Et-Gua in brain and liver of MNU- or ENU-treated mice or rats [36,40, 41]. *O*<sup>6</sup>-Me-Gua and *O*<sup>6</sup>-Et-Gua adducts are actively repaired in liver but not in the brain, the target tissue of MNU and ENU tumorigenesis in rats [80]. After a single exposure, *O*<sup>6</sup>-guanine adducts are readily removed in the repair-proficient hepatic tissue but remain relatively persistent in the repair-deficient brain tissue. In contrast, the chemically less stable *N7*-Et-Gua and *N3*-Et-adenine adducts have similar elimination rates in both tissues, suggesting that these adducts are lost due to spontaneous depurination [40,41]. Consequently, the ratio of *N7*-Et-Gua to *O*<sup>6</sup>-Et-Gua decreases in target tissues with time and duration of exposure, and the presence of *N7*-guanine adducts does not predict a fixed amount of *O*<sup>6</sup>-guanine adducts. Most importantly, the presence of *N7*-guanine adducts cannot serve as quantitative indicator for the existence of other mutagenic or genotoxic lesions, without reliable knowledge of the half-lives in tissue and time since exposure. Although ratios of formation of related adducts can be expected to following *in vitro* chemistry, tissue-specific differences in repair and stability of the individual adducts will alter adduct-distribution and this dynamic must be considered in subsequent interpretations.

## 2.2 Nitrosamines

Nitrosamines are a class of chemical compounds that were first described in the chemical literature over 100 years ago, but not until 1956, did they receive much attention. During a routine screening of chemicals that were being proposed for use as solvents in the dry cleaning industry, John Barnes and Peter Magee, reported that dimethylnitrosamine (DMN) produced liver tumors in rats [81]. Magee and Barnes' landmark discovery caused scientists around the world to investigate the carcinogenic properties of other nitrosamines and *N*-nitroso compounds. Approximately 300 of these compounds have been tested, and 90% of them have been found to be carcinogenic in a wide variety of experimental animals, with many of them exhibiting organ specificity in their carcinogenicity [74]. For instance, DMN causes liver, kidney, and lung cancer in experimental animals, and some of the tobacco-specific nitrosamines are very potent pulmonary carcinogens [82-85]. *N*-nitrosamines require metabolic activation to exhibit their mutagenic and carcinogenic effects. Metabolic activation of nitrosamines is catalyzed by various forms of P450 enzymes in reactions that in general form a highly reactive diazonium ions and aldehydes [86]. Both the diazonium ions and the aldehydes form DNA adducts, including *N7*-guanine adducts (Figure 2).

***N,N*-Dimethylnitrosamine (DMN)** is potent rodent carcinogen inducing liver, kidney, and lung tumors, with mice being more susceptible than rats [81,87]. To investigate potential mechanisms responsible for species differences, the formation of *N7*-Me-Gua and *O*<sup>6</sup>-Me-Gua were determined in mice and rats treated with DMN [88]. The experimental results of this study indicated distinct differences in rat and mouse hepatocytes for repair of the promutagenic DNA lesion, *O*<sup>6</sup>-Me-Gua. The ratio of *N7*-Me-Gua to *O*<sup>6</sup>-Me-Gua indicated similar repair of *O*<sup>6</sup>-Me-Gua at low DMN exposures in rats and mice. However, the ratios of *N7*-Me-Gua to *O*<sup>6</sup>-Me-Gua changed with increasing DMN dose, suggesting differential ability of these 2 species to repair increasing amounts of *O*<sup>6</sup>-Me-Gua. This difference was due to readily inducible *O*<sup>6</sup>-

methylguanine DNA-methyltransferase ( $O^6$ MT), found in the rat liver, but not the mouse. Pegg and Hui [89] first observed that the dose-response curves for  $O^6$ -Me-Gua induced by DMN were different from that of  $N^7$ -Me-Gua. Studying DNA adducts derived from DMN, it was noticed that the amounts of  $O^6$ -Me-Gua were much lower relative to  $N^7$ -Me-Gua at low exposures than at high exposures. The ratio of  $N^7$ -Me-Gua to  $O^6$ -Me-Gua at high doses was approximately 10, while at lower exposure the amounts of  $N^7$ -Me-Gua were about 100-fold higher than that of  $O^6$ -Me-Gua [89]. The change in ratio of  $N^7$ -Me-Gua to  $O^6$ -Me-Gua was later shown to be a result of depletion of  $O^6$ MT at high doses.  $O^6$ MT is a highly efficient and specific DNA repair protein that selectively repairs  $O^6$ -Me-Gua.  $O^6$ MT removes the alkyl groups from the  $O^6$ -guanine position by transferring them to the protein itself, effectively restoring the guanine base in DNA, and thereby inactivating the protein [90]. Thus at low exposures  $O^6$ -Me-Gua adducts are effectively repaired by  $O^6$ MT producing a higher  $N^7$ -Me-Gua to  $O^6$ -Me-Gua ratio. As exposure increases, this  $O^6$ -Me-Gua specific DNA repair system is depleted and amounts of  $O^6$ -Me-Gua start to accumulate at a rate similar to their chemical formation. This may explain why early studies of adduct distribution with relative high exposures suggested that the adduct distribution *in vivo* is similar to the reaction of alkylating compounds with isolated DNA *in vitro* [8]. However as methodology improved, measurement at lower exposure concentrations were possible and differences in adduct profiles depending on exposures and tissue types were observed. Subsequent advancements in DNA repair research enabled correlation of specific DNA adduct profiles with repair capacities. In general, the dose response for  $N^7$ -Me-Gua is linear, while it is sub-linear for  $O^6$ -Me-Gua in  $O^6$ MT repair proficient tissues. The slope of the upper portion of such a sub-linear dose response is similar to that of  $N^7$ -Me-Gua and represents the chemical formation rate, since proportionately fewer adducts are removed by repair enzymes like  $O^6$ MT. At low exposures  $O^6$ -alkylguanine adducts are readily repaired in most tissues. Consequently, at higher exposures where DNA repair activity is saturated the number of DNA adducts formed increases per unit dose of carcinogen, producing a non-linear dose-response.

**4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)**, a tobacco-specific nitrosamine is a potent pulmonary carcinogen inducing lung tumors in experimental animals independent of route of exposure [83]. NNK is metabolically activated in several tissues by an P450-catalyzed hydroxylation of the methylene or methyl carbon adjacent to the *N*-nitroso group ( $\alpha$ -hydroxylation, reviewed by Jalas et al. [91]). These hydroxylation reactions form unstable intermediates that spontaneously decompose to reactive diazonium ions, which can form DNA adducts including  $N^7$ -guanine adducts, and formaldehyde (Figure 2)[92-100], as reviewed by Hecht [82]. The formation of NNK-derived  $N^7$ -Me-Gua and  $O^6$ -Me-Gua has been observed in a number of tissues including placenta, esophagus, larynx, liver, and white blood cells (WBC) [101]. The dose-responses for  $N^7$ -Me-Gua and  $O^6$ -Me-Gua in NNK-treated rat lung and liver tissues are similar in shape to the ones observed after DMN treatment discussed above. The dose-responses for  $N^7$ -Me-Gua and  $O^6$ -Me-Gua are supra-linear in the lung and liver of NNK-treated rats due to saturation of the  $\alpha$ -hydroxylation step in metabolic activation [102]. Furthermore, in lung the persistence of  $O^6$ -Me-Gua was greatest in Clara cells, the progenitor cells for nitrosamine-induced lung tumors [67,103,104]. NNK metabolism was shown to be greatest in Clara cells followed by alveolar macrophages, type II cells and minor in alveolar small cells (300, 220, 100, <10 mol/10<sup>6</sup>cells/1h, respectively), demonstrating cell specific activation [69,69,103]. In addition,  $O^6$ MT activity was 2-fold greater in macrophages and Type II cells than in alveolar small cells or Clara cells [69,69,103]. Therefore, the Clara cell-specific accumulation of  $O^6$ -Me-Gua in rats was attributed to reduced  $O^6$ MT activity coupled with a high capacity for NNK activation.

## 2.3 Hydrazines

Similar to nitrosamines, hydrazine compounds have been studied both as potential anticancer drugs and as cancer-causing agents. Early studies of hydrazines, including hydrazine sulfate, were conducted and these compounds were found to induce tumors in laboratory animals [105-107]. Hydrazines require metabolic activation to exhibit their carcinogenic effects and experiments with rat liver microsomes suggested involvement of P450s [108]. Treatment of mice, rats or hamsters with hydrazines substantially increases the incidence of several tumor types [107]. When administered by gavage, 1,2-dimethylhydrazine (SDMH) increased the incidence of lung tumors in female mice. When administered in drinking water, SDMH induced high incidences of angiosarcomas in various organs and tumors of the kidneys, lungs, and liver in mice of both sexes [107]. The same route of administration induced liver carcinomas and angiosarcomas in rats.

Herron and Shank [109] investigated the time course of *N*7-Me-Gua in liver and kidney of rats over a 25-week period, during which the animals received 21 mg/kg SDMH s.c., once every week during the first 14 weeks. During the treatment period, *N*7-Me-Gua adducts accumulated in liver and kidney and then were below the limit of detection of 156 *N*7-Me-Gua/10<sup>7</sup> nnt six or 11 weeks post treatment. No adducts were found in non target tissues (lung or pancreas) [109]. Unfortunately, the limit of detection at these early studies was not sufficient to determine potential endogenous amounts of *N*7-Me-Gua, which are discussed in detail below. This study clearly demonstrated that metabolic activation, and subsequent adduct formation was tissue-specific, and that reactive hydrazine metabolites were not stable enough to diffuse to distant sites.

Surprisingly, in rats no adduct accumulation was found in colon, another target site for SDMH tumorigenesis [110-112]. In colon DNA, *N*7-Me-Gua and *O*<sup>6</sup>-Me-Gua have the same half-life, ~30 h, which is much lower than the ~150 h determined in other tissues [29]. Therefore, the removal of *N*7-Me-Gua and other DNA adducts in colon is to a greater extent dependant on cell division and sloughing compared to liver, where DNA repair and spontaneous depurination are responsible for adduct removal [113]. *O*<sup>6</sup>-Me-Gua accumulated in kidney, while in liver it was only detected after the first SDMH treatment, adding support to the inducibility of *O*<sup>6</sup>MT in rat liver, but not in kidney, one of the main target organ of SDMH-induced tumorigenesis [89,114].

Furthermore, metabolic activation, detoxication, and DNA repair can be different among cell types. The first evidence for different DNA adduct profiles between cells within a target organ was demonstrated in rats exposed to single [32] or chronic [115] doses of SDMH. Swenberg and colleagues investigated the formation and persistence of *N*7-Me-Gua and *O*<sup>6</sup>-Me-Gua in individual liver cell types. SDMH induces mainly malignant liver angiosarcoma [116-118]. Analysis of *N*7-Me-Gua in purified non-parenchymal cells (NPC), the origin of angiosarcomas, compared with hepatocytes demonstrated similar increases in both cell types, confirming even distribution of exposure between cell types. The corresponding amounts of *O*<sup>6</sup>-Me-Gua were significantly different, with amounts in hepatocytes peaking one day after exposure and then declining to 1/30 of the initial amounts, while in NPC cells, amounts of *O*<sup>6</sup>-Me-Gua steadily accumulated for 8 days [119]. The significant decline of *O*<sup>6</sup>-Me-Gua in hepatocytes was due to both constitutive and an additional 4-fold enhancement of *O*<sup>6</sup>MT activity during continuous exposure, an activity that is much lower and remained constant in NPC cells [119].

**Summary**—Even though *O*<sup>6</sup>-Me-Gua was identified as the potentially promutagenic adduct in the examples described above, it would have been difficult to come to such a conclusion without normalization of the data to *N*7-Me-Gua. These and other studies with pro-carcinogens clearly established that metabolic activation of carcinogens and DNA alkylation can be species-, strain-, tissue-, and cell-type specific. In addition, evidence has been reported that



adduct formation rates and endogenous background levels could be age-dependent, and are modified by DNA repair. Consequently, these studies have greatly advanced our understanding in the origin and molecular mechanisms of tissue specificity of these model carcinogens. Unfortunately, as has been described above, the ratio of *N7*-guanine adducts to other DNA adducts (*e.g.*, *O*<sup>6</sup>-guanine adducts) is not constant and is heavily dependent on time since exposure, dose, species, tissue, and cell type. Therefore, to use *N7*-guanine adducts as a surrogate biomarker for other DNA adducts, it is essential to have detailed knowledge of the rate of formation and persistence of *N7*-guanine adducts, and the corresponding adducts of interest.

#### 2.4 Olefins: ethylene, propylene, butadiene, and their metabolites

Olefins are characterized by one or more double bonds, with ethylene (ET), propylene, and 1,3-butadiene (BD) being the best studied in respect to DNA adduct formation. BD and the ET metabolite, ethylene oxide (EO), have been classified as human carcinogens [120]. Occupational exposure to butadiene has been associated with increased risk for leukemia in workers exposed to BD in synthetic rubber production [121-123] and an increase in lymphohematopoietic cancers in BD monomer production workers that was not exposure related [124]. Olefins are mainly metabolized by P450s to the corresponding epoxides that are known to form DNA adducts, including *N7*-guanine adducts *via* S<sub>N</sub>2 reactions (Figure 3). These olefin epoxides are more stable than the reactive metabolites discussed above (diazonium ion, hydrazine, *etc.*) and they circulate freely throughout the body. Consequently, DNA adducts are formed in similar amounts in target and non target tissues [68,125-127]). The main adducts of olefin epoxides are the corresponding *N7*-guanine adducts, and *N3*-adenine adducts in addition to other minor adducts. The relative reactivities of nucleophilic sites in DNA toward some olefin epoxides are shown in Table 1.

**Ethylene and ethylene oxide**—ET is metabolically activated by P450s to ethylene oxide (EO) and forms *N7*-hydroxyethyl-guanine (*N7*-HE-Gua) as its major DNA adduct. Inhalation studies with ET in mice and rats established supra-linear dose-responses over the exposure concentrations studied, suggesting saturation of the metabolic activation [128,129]. The metabolism of ET to EO in mice saturates at ~1000 ppm ET [130,131], producing in liver ~3.5 *N7*-HE-Gua/ 10<sup>7</sup> nnt (Table 2, Figure 4) [33,132,133]. In contrast, a linear dose-response for *N7*-HE-Gua has been found in experiments with mice or rats exposed to EO over a wide range of exposures (Figure 4)[133,134]. The molecular dose of *N7*-HE-Gua can be orders of magnitude greater for exposures to EO than can ever be achieved by ET. In subacute or chronic exposures to EO, *N7*-HE-Gua adducts increase daily until they reach a steady state after 7-10 days [33]. This supra-linear response over time is attributed to the chemical instability of *N7*-HE-Gua. At steady state, the number of *N7*-HE-Gua adducts formed is equal to the number of adducts lost due chemical depurination or cell death.

All animals and humans are constantly exposed to ET and EO produced by numerous endogenous metabolic processes and by conversion of ET to EO by the liver [135,136]. Additional EO exposures are from numerous food products that can contain up to <0.05 to 1800 µg ET/g [137]. The endogenous formation and steady exposure *via* the diet produces a background level of *N7*-HE-Gua that has been observed in mice, rats, and humans [128, 138-143]. Yong *et al.* reported *N7*-HE-Gua in granulocytes from humans that were not exposed to known sources of ET or EO [143]. The presence of endogenous EO exposure in humans has been confirmed by detection of hydroxyethyl-valine hemoglobin adducts, another EO-specific biomarker [144,145]. Endogenous or background amounts in mice and rats were in the range of 1-18 *N7*-HE-Gua adducts/10<sup>7</sup> nnt [132,133,146-148]. The existence of endogenous *N7*-guanine adducts has to be accounted for in mechanism-based risk assessments and evaluations of low exposures [27].

**Propylene and propylene oxide**—Propylene is metabolically activated by P450s to propylene oxide (PO) and forms *N*7-hydroxypropyl-guanine (*N*7-HP-Gua). The formation of *N*7-HP-Gua in rat liver saturates at exposures greater than 2000 ppm propylene and produces about 6.5 adducts /10<sup>7</sup> nnt (Figure 4) [149]. In contrast, exposures to the activated oxide, PO, produces almost 200-fold greater amounts of *N*7-HP-Gua and the dose-response is linear (Figure 4). Comparing the adduct amounts formed after propylene and PO exposures, it can be estimated that a maximum of 0.5% of the propylene dose is activated to PO and associated with DNA adduct formation. The fact that the adduct formation appears linear for PO-derived *N*7-HP-Gua and that exposures to PO produce much higher amounts of these adducts demonstrates that adduct formation is not limited by available binding sites in DNA or induction of specific DNA repair systems. Therefore, the saturation observed with propylene is due to saturation of the metabolic activation and/or induction of detoxification pathways. Similar data were obtained from a variety of chemicals and are summarized in Table 2.

**Butadiene and butadiene-derived epoxides**—1,3-Butadiene (BD) is an olefin of special interest because it is metabolized to several reactive epoxides (Figure 3)[150]. All BD-derived epoxides are known to form DNA and protein adducts. Although the different oxidation reactions are catalyzed by the same enzymes, mainly by P450 2E1, 2A6 and 3A4, the dose-responses of their internal formation are vastly different in mice, rats, and humans [151,152]. BD is first oxidized to 1,2-epoxy-3-butene (EB), a metabolite known to form 2-hydroxy-3-butenyl DNA and protein adducts. To date, the *N*7-(2-hydroxy-3-butenyl)-guanine and *N*7-(1-hydroxy-3-butenyl)-guanine (*N*7-HB-Gua)\* are the only EB-specific *N*7-guanine adducts found in mice and rats exposed to BD (Figure 3)[68]. The dose-response for *N*7-HB-Gua has been shown to be linear in mice and rats from the lowest exposure studied (20 ppm BD 4 weeks) to high exposures known to induce tumorigenesis [68]. The presence of a minor adduct, *N*1-HB-Ade, has been reported in rat liver after 5 days of exposure to 300 ppm BD [153] and its formation was about 3-fold lower than the *N*7-HB-Gua.

*In vitro* formation of *N*3-HB-adenine, *N*<sup>6</sup>-HB-adenine, and *N*1-HB-inosine adducts have been identified, but their existence *in vivo* has not been shown [154,155]. Of these theoretical adducts, *N*1-HB-inosine is of special interest, since it has the highest mutagenic potency (>95% per replication cycle) [156,157]. The mutagenic potencies were significantly lower (<1%) for *N*2-HB-guanine and *N*<sup>6</sup>-HB-adenine [158]. Unfortunately, the *N*7-HB-Gua adduct is not suitable for site-directed mutagenesis studies because of its chemical instability that leads to spontaneous depurination. Therefore, the specific mutagenic potency of *N*7-HB-Gua remains to be assessed, although mutagenic potency may be very low given that *N*7-guanine adducts are relative unstable and do not participate in hydrogen bonding in the DNA double helix [2].

EB can undergo a second oxidation reaction, catalyzed by P450s 2E1, 2C9, and 2A6, producing the 1,2;3,4-diepoxybutane (DEB) [159], which is a bi-functional carcinogen that can form DNA-DNA [160-162] and DNA-protein crosslinks (Figure 3)[163,164]. *In vivo*, the presence of *N*7-guanine-*N*7-guanine [1,4-bis(guan-7-yl)-2,3-butanediol (bis*N*7-Gua-BD-diol)] and *N*7-guanine-*N*1-adenine [1-(guan-7-yl)-4-(aden-1-yl)-2,3-butanediol (*N*7-Gua-*N*1-Ade-BD-diol)] were observed in liver and lung of mice exposed by inhalation to 625 ppm BD [160, 161]. The bis*N*7-Gua-BD-diol is a weak mutagen, producing miscoding in less than 1% of all replication cycles, compared to the more mutagenic *N*<sup>6</sup>,*N*<sup>6</sup>-adenine intrastrand cross-links, which produce miscoding in 8% of the replication cycles, [156,157]. The dose-responses of bis*N*7-Gua-BD-diol and *N*7-Gua-*N*1-Ade-BD-diol cross links were recently reported in mice and rats [165]. It was shown that mice form much more DEB than rats and that adduct formation was higher in lung and liver compared to kidney, brain and thymus. The tissue difference

\*The abbreviation *N*7-HB-Gua will be used for both the *N*7-(2-hydroxy-3-butenyl)-guanine and *N*7-(1-hydroxy-3-butenyl)-guanine (*N*7-HB-Gua).

appears to be due to the high reactivity of the bi-functional DEB compared to the mono-functional EB or EB-diol and suggests DEB formation in liver and lung tissue. Further, formation of DEB seemed to saturate in rats at exposures above 62.6 ppm BD and showed a decrease in slope in mice at exposures above 200 ppm. This dose-response for DEB derived adducts have been confirmed by the analysis of *N,N*-(2,3-dihydroxy-1,4-butadiyl)-valine (*pyr*-Val), the corresponding DEB-specific globin adduct, in the same animals (Georgieva et al in preparation).

The epoxides EB and DEB can be hydrolyzed by epoxide hydrolase (EH) producing 3-butene-1,2-diol (BD-diol) and 1,2-epoxy-3,4-butanediol (EB-diol), respectively [151, 166-171]. The latter, EB-diol, can also be formed by a second oxidation of BD-diol [167, 171]. Analysis of the EB-diol-derived *N7*-(trihydroxybutanyl)-guanine (*N7*-THB-Gua) adducts demonstrated that EB-diol is the main BD-derived epoxide in mice and rats (Figure 3)[68]. Most interestingly, while the dose-response for *N7*-HB-Gua (EB-derived) is linear, the dose-response for *N7*-THB-Gua (EB-Diol derived) shows saturation at exposures greater than 62.5 ppm BD in rats after 20 days of exposure, and its slope of formation is reduced with higher exposures in mice [68]. In addition, using *N7*-HB-Gua and *N7*-THB-Gua, it was shown that mice form much more EB and EB-diol than rats, a finding that is consistent with the higher susceptibility of mice to BD induced tumorigenesis.

BD species-dependent tumorigenesis is attributed to species-specific differences in BD metabolism. The formation of *N7*-guanine adducts support the hypothesis that mice are more susceptible because they are more efficient at BD oxidation. Molecular modeling of P450 2E1 also suggested significant species differences between mouse, rat, and human in BD oxidation [172]. The species differences in formation of *N7*-HB-Gua, DEB-derived cross-link adducts and *N7*-THB-Gua has been confirmed using the corresponding globin adducts hydroxybutenyl-valine (HB-Val), *pyr*-Val and trihydroxy-butanly-valine (THB-Val), suggesting that the corresponding hemoglobin adducts are a good biomarker for formation of these reactive metabolites [173,174]. Lastly it was shown that EB can bind to human P450 2E1 itself [175], and may alter catalytic activity in a similar fashion as the mechanism-based inhibition by other P450 substrates including ET [176-186]. Thus, monitoring *N7*-HB-Gua may provide a biomarker for functional changes in the metabolic pathways, possibly due to alkylating inactivation of important enzymes.

In summary, the studies with olefins described above clearly demonstrate that direct alkylating agents produce a linear dose-response for *N7*-guanine adducts vs dose, confirming the validity of *N7*-guanine adducts as a biomarker for internal dose. In contrast, adducts resulting from metabolites of metabolically activated compounds show strong species differences and usually exhibit supra-linear dose-response curves. This is primarily due to saturation of metabolic activation or changes in detoxification pathways, which means that the *N7*-guanine adducts are better dosimeters for internal dose than administered dose, especially if quantified in tissues of interest. In chronic exposure situations, steady state levels are typically reached after 7-10 days for both olefins and their epoxide metabolites.

### 3 Formation of *N7*-guanine adducts in human specimens

Despite the ubiquitous nature of *N7*-guanine adducts, their application as a biomarker of exposure in larger molecular epidemiology studies is not common practice. A review of the literature demonstrated limited numbers of studies using *N7*-guanine adducts as biomarkers for exposure to environmental or occupational pollutants. Furthermore, reported data are not extensive and mostly contain small numbers of individuals per group.

Similar to the data from animal studies, the presence of *N7*-Me-Gua and other *N7*-guanine adducts has been demonstrated ubiquitously in DNA from humans not known to be exposed

to alkylating agents (Table 3) [146,187-196]. Most of these reports investigated DNA from blood samples; either white blood cells (WBC) or individual blood cell types, and measured *N7*-Me-Gua by <sup>32</sup>P-postlabeling or HPLC-ECD. While this seems to be sufficient evidence for the presence of *N7*-Me-Gua from endogenous sources in human DNA, it needs to be mentioned that the numbers of subjects per group in most of these studies were relatively small ( $\leq 20$ ). The amount of *N7*-Me-Gua in controls, representing endogenous or background adducts, were about half of the amounts reported for the exposed groups, which were primarily smokers. Consequently, the statistical power of these studies is reduced because of the small number of subjects and the limited difference between controls and exposed individuals. Furthermore, it is not possible to differentiate endogenous adducts from background adducts, *e.g.*, formed from potential environmental sources due to their indistinguishable chemical identity. Interestingly, *N7*-Me-Gua amounts were 3-fold and 5-fold higher in tumor tissue compared to normal tissues from cervical or bladder tissues, respectively [187,194]. In contrast, *N7*-Me-Gua amounts were lower in colon tumor DNA compared to normal colon tissue [192]. The amounts of *N7*-Me-Gua in all controls (representing endogenous background amounts) range from 0.8 to 13.5 adducts/ $10^7$  nnt compared to 3.9 to 23.6 adducts/ $10^7$  nnt in the exposed subjects from the corresponding study groups. Evaluation of *N7*-Me-Gua amounts in lymphocyte DNA and solid tissues suggest slightly higher amounts in solid tissues, however sample numbers are small (Table 3).

Wu *et al.* reported mean endogenous amounts of  $4.8 \pm 3.1$  *N7*-HE-Gua adducts /  $10^7$  nnt in lymphocytes (n=23) of unexposed humans [128]. More recently, Yong *et al.* [143] demonstrated the presence of *N7*-HE-Gua in granulocytes of hospital workers not known to be exposed to sources of ET or EO [143]. The mean amount of *N7*-HE-Gua was  $9.6 \pm 5.8$  adducts/ $10^7$  nnt in subjects categorized as unexposed controls. The range of these amounts is similar as reported previously for five control subjects [141]. These *N7*-HE-Gua background amounts are believed to stem from EO that forms endogenously from ET derived from environmental exposures such as vegetation, urban air, smoking, and various endogenous metabolic processes [137,197-199]. Tompkins *et al.* report in this special issue evidence of increased *N7*-HE-Gua in rat tissue due to oxidative stress [200].  $H_2O_2$  may catalyze the formation of ET from methionine, similar to the ET production in fruits and vegetables [201, 202]. The confirmed presence of background DNA alkylation (*N7*-Me-Gua and *N7*-HE-Gua) from environmental and endogenous sources in humans is relevant for consideration in risk assessments used to make regulatory decisions. No evidence for endogenous *N7*-HP-Gua and *N7*-THB-Gua have been reported, although presence of hydroxypropyl-valine (HP-Val) and THB-Val, the corresponding PO- and EB-diol-specific globin adducts, have been reported in subjects or animals not exposed to known sources of propylene, BD or their epoxide metabolites, PO and EB-diol, respectively [126,203,204]. This may suggest that additional unknown endogenous *N7*-guanine adducts may exist that need to be considered.

## 4 Evidence for mutations resulting from *N7*-guanine adducts

### 4.1 *N7*-Me-Gua and *N7*-Et-Gua and mutagenesis in mammalian cells

Early efforts aimed to compare DNA alkylation with mutation frequency (MF) and mutation spectra to identify adducts involved in mutagenesis. Beranek *et al.* reported a good correlation between DNA methylation (*N7*-Me-Gua and *O*<sup>6</sup>-Me-Gua) and mutation frequency (MF) in the *HPRT* gene in CHO cells after treatment with MMS or MNU [205]. In contrast, the formation of *N7*-Et-Gua did not correlate with mutation frequency in *HPRT* or Na-K-ATPase genes in CHO cells treated with diethylsulfate (DES), EMS, or ENU [206]. The formation of *N7*-Et-Gua was linear with exposures for each ethylating agent, but the slopes were significantly different. In contrast to the *N7*-Et-Gua, the amounts of *O*<sup>6</sup>-Et-Gua adducts induced by all three ethylating agents correlated with MF in the *HPRT* gene, while the MF in the Na-K-ATPase gene correlated only with EMS and ENU, and not with DES [206]. This suggests that such

correlation studies may be inadequate to analyze multi-component phenomena like mutagenesis, and that DES induces mutations by a mechanism not involving *N7*-Et-Gua adducts.

Methyl methanesulfonate (MMS) predominantly produces *N7*-Me-Gua (~92%) in DNA and a very low percentage of mutagenic *O*<sup>6</sup>-Me-Gua (~0.3%) [21]. In Chinese hamster ovary (CHO) cells exposed to MMS at 0.75 mM for 1 hour, the majority of *HPRT* mutations were GC to AT transitions [207], with no increase in other types of mutations. This type of mutation is also found in other Chinese hamster cell lines following exposure to MMS either at 2 mM for 30 minutes or at 1 mM for 1 hour [208,209]. In these three studies, MMS appears to introduce 750 to 1000 *N7*-Me-Gua/10<sup>7</sup> nnt, 0.8 to 1.0 *N3*-Me-dAde/10<sup>7</sup> nnt, and 0.027-0.036 *O*<sup>6</sup>-Me-Gua/10<sup>7</sup> nnt roughly estimated from our data and from the ratio of *N7*-Me-Gua/*N3*-Me-Ade/*O*<sup>6</sup>-Me-Gua = 83/8.7/0.3 [21]. It was concluded that this specific GC to AT transition is most likely caused by mispairing of *O*<sup>6</sup>-Me-Gua with thymine during replication and cell division [210,211]. These results strongly suggest that AP sites likely formed by spontaneous depurination of *N7*-Me-Gua do not contribute to the induction of *HPRT* mutations in these MMS-exposed cells. Interestingly, preliminary results from our lab show that an imbalance of base excision repair (BER) repair in CHO AA8 cells may start at exposure to 1.9 mM MMS for 1 hour as determined by the extent of depletion of intracellular NAD(P)H in cells (Figure 5) (Pachkowski, unpublished data). Therefore, if the *N7*-Me-Gua are 1000 lesions/10<sup>7</sup> nnt or less and *N3*-Me-Ade are 100 lesions/10<sup>7</sup> nnt or less, the increase in *HPRT* mutations in cells exposed to MMS can all be accounted for by induction of *O*<sup>6</sup>-Me-Gua (0.036 lesions/10<sup>7</sup> nnt or less) and are not due to formation of AP sites as BER intermediates.

#### 4.2 *N7*-HE-Gua and *N7*-HP-Gua and mutagenesis

The formation of *N7*-HP-Gua saturates at levels of 6.5 adducts /10<sup>7</sup> nnt in rats after 20 days of exposure to propylene (Table 2, Figure 4) [149]. This amount is 15-fold lower than the molecular dose associated with induction of mutations in *Drosophila* [212]. In that study, male *Drosophila* exposed to PO for 24 h did not show a significant increase in mutations until the internal dose, measured as *N7*-HP-Gua adducts, reached approximately 100 adducts /10<sup>7</sup> nnt. Since no other adducts were measured, these data do not demonstrate that *N7*-HP-Gua was the causal adduct. Together, these reports provide mechanistic evidence that propylene is not mutagenic. Pottenger *et al.* [149] demonstrated that metabolic activation of propylene does not produce sufficient numbers of DNA adducts in mice or rats, compared to that associated with mutagenesis in *Drosophila* [212]. Furthermore, the *Drosophila* system most likely over estimates the mutagenic potency of PO since cell proliferation is much faster in the *Drosophila* gonadocytes, leaving less time for DNA repair compared to mammalian systems.

The range of *N7*-guanine adducts of 0.8-23 adducts /10<sup>7</sup> nnt in humans, summarized in Table 3, are significantly below the *N7*-HP-Gua adducts shown to correlate with mutations in *Drosophila*. In contrast, significant increases in mutations in *Drosophila* after EO exposure were accompanied by 30 *N7*-HE-Gua/10<sup>7</sup> nnt. However NER repair decreased the EO-induced mutation response in *Drosophila*, suggesting involvement of adducts other than *N7*-HE-Gua in mutagenesis [212]. This adduct amount is close to the amounts observed in hospital workers exposed to EO as a sterilant and only 3 to 6-times higher than the background level of endogenous *N7*-HE-Gua [143]. These data may suggest that the large background of endogenous DNA adducts, derived from endogenous metabolites arising from oxidative stress and endogenous ET may significantly contribute to background mutagenesis [200,213]. This is an area that clearly needs additional research.

### 4.3 AP sites derived from *N7*-guanine adducts

Apurinic sites (AP) are the most common form of endogenous DNA damage and are the product of spontaneous depurination, oxidative damage, and the result of DNA repair. The notion that *N7*-guanine adducts convert to AP sites and subsequently cause mutations was investigated by Rusyn *et al.* [129]. It was demonstrated that AP sites are not increased following repeated exposure to ET or EO; the presence of *N7*-HE-Gua indicates that AP sites would be formed by spontaneous depurinations, so they must be efficiently repaired so that they do not cause any increase over the endogenous level [129]. In addition, the *HPRT* mutation frequency in mice and rats, and micronuclei in polychromatic or normochromatic erythrocytes (MNPCE) in rats, were not increased after repeated exposures to 3000 ppm ET, while the *N7*-HE-Gua adducts significantly increased over endogenous levels and their formation saturated at exposures of 3000 ppm ET. This exposure resulted in 6 adducts /10<sup>7</sup> nnt (Table 2) [33]. In contrast, exposures of 100 ppm EO significantly increased *HPRT* mutation frequency and MNPCE [33,214], but still did not result in accumulation of AP sites [129]. The number of AP sites ranged from 30 to 70 AP sites /10<sup>7</sup> nnt for controls, ET-, and EO-exposed rats, while the number of *N7*-HE-Gua increased more than 10-fold from ~6 to 64 /10<sup>7</sup> nnt in rats exposed to 0 or 100 ppm EO for 4 weeks, respectively [129]. The authors concluded that the mutagenesis from EO exposures most likely resulted from minor promutagenic adducts, rather than AP sites or *N7*-HE-Gua. Measurement of AP sites after neutral thermal hydrolysis of DNA confirmed that EO produced heat labile lesions as a result of enhanced depurination. Heat-treated spleen DNA had a 5-fold increase in AP sites after EO exposure [129].

Similarly, PO exposures did not increase AP sites in nasal epithelium, the target tissue for PO carcinogenesis, despite the high internal dose of *N7*-HP-Gua, with up to ~1000 *N7*-HP-Gua / 10<sup>7</sup> nnt in rats exposed to 500 ppm PO for 4 weeks [215]. While the number of adducts was much lower than that found after high PO exposures, 4 week inhalation exposures to 10,000 ppm propylene did not increase the mutation frequency in the *HPRT* gene in spleenocytes [149].

AP sites are also intermediates of BER, however, formation from enzymatic removal of *N7*-guanine adducts is minimal, compared to those arising from spontaneous depurination. This area is not fully understood, however, enzymatic removal has been shown to reduce the half-lives of some *N7*-guanine adducts to minutes instead of hours [216-218]. The bacterial enzyme AlkA has been shown to remove a wide variety of damaged purine and pyrimidine bases, including *N7*-Me-Gua [219-221]. Mammalian cells do not possess a homologue of AlkA, but AAG, a member of the *N*-methylpurine DNA glycosylase family, removes a broad spectrum of modified purines from DNA including *N7*-Me-Gua [222,223]. Additional studies on knockout animals will be needed to demonstrate that DNA repair plays a significant role in removal of *N7*-guanine adducts, compared to chemical depurination.

### 4.4 Mutations induced by BER intermediates in mammalian cells

To characterize the mutagenic potential of AP sites, a BER intermediate in mammalian cells, an SV-40-derived shuttle vector with a single lesion of either an abasic (AP) site or 5'-deoxyribose-5-phosphate (5'dRp: 5'-cleaved AP sites), at a defined position, was transfected into monkey kidney COS7 cells [224]. The mutation spectrum revealed that preferential incorporation opposite the AP sites is dA (48%) > dC (39%) > dG (13%) >> dT (none). Thus, if either dA or dC is incorporated opposite the AP sites derived from depurination of *N7*-guanine adducts, GC->TA transversions are expected as the primary mutation induced by AP sites. In addition, a small proportion (16%) of deletions was also observed [224]. During BER, the AP sites are converted into single strand breaks (SSB) by AP endonuclease 1, which leads to the formation of 5'dRp and 3' hydroxyl termini. In the same vector system, the mutation analysis showed that preferential incorporation opposite the 5'-dRp was dA (46%) > dG (41%)

» dC (13%) » dT (none). As with AP sites, a small proportion (9%) of deletions was observed. Therefore, *N7*-guanine adducts are expected to cause G->T transversions, G->C transversions, and deletions if they result from products of BER intermediates 5'dRp and AP sites. In contrast, the nitrosamine DMN and ENU induce mainly G->A transition mutations in the BigBlue transgenic mice model [225-228]. In CHO cells, MMS primarily increases GC to AT transitions in the HPRT gene [207]. In splenic T-lymphocytes of mice, EO induced four A:T transversions, three A:T transitions, two G:C transversions, and two G:C transitions [229]. In *in vitro* and *in vivo* test systems, BD and its metabolites, EB, DEB, and EB-diol induce predominantly deletions and base substitutions at A:T [230-232]. Consequently, the mutation spectra are quite different for compounds known to form *N7*-guanine adducts that can convert to AP sites, than the mutation spectrum produced by AP sites.

#### 4.5 Ring-opened formamidopyrimidine adducts (FAPy adducts)

*N7*-guanine adducts are susceptible to attack by hydroxide on the C8 carbon and subsequent ring opening to form 5-*N*-alkyl-2,6,-diamino-4-hydroxyformamidopyrimidine (Alkyl-FAPy) [233-241]. Early studies [233,239] proposed placement of a formyl group (-CHO) on the *N7*-position and this has been confirmed by NMR examination of 5-*N*-methyl-2,6,-diamino-4-hydroxyformamidopyrimidine (Me-FAPy) and 5-*N*-(9-hydroxyafatoxin)-2,6,-diamino-4-hydroxyformamidopyrimidine (AFB<sub>1</sub>-FAPy) [242,243]. During the ring opening, the negative charge on the N9-position is delocalized to an  $\alpha$ - $\beta$ -unsaturated carbonyl by the pyrimidine ring, subsequently stabilizing the glycosidic bond. This has important biological implications since, unlike the *N7*-guanine adduct, the Alkyl-FAPy will not spontaneously depurinate and be lost from DNA. In fact it has been shown that the Me-FAPy was more persistent in rat bladder epithelium than *O*<sup>6</sup>-Me-Gua after 21 days and accounted for approximately 72% of the total MNU-derived adducts [244]. In rat liver Me-FAPy was the main persistent adduct after DMN and SDMH treatment [245]. There is an urgent need for more data on the amount of Me-FAPy and other FAPy adducts in cells and tissues in exposed and control animals.

For example, aflatoxin, one of the most potent liver carcinogens, is metabolically activated to the 8,9-epoxide which forms primarily *N7*-AFB<sub>1</sub>-Gua [246-252]. The *N7*-AFB<sub>1</sub>-Gua converts to secondary lesions including AP sites and AFB<sub>1</sub>-FAPy. Compared to *N7*-AFB<sub>1</sub>-Gua, AFB<sub>1</sub>-FAPy is highly persistent in rat liver DNA, reaching maximum amounts 2 weeks after exposure [249]. While the structures of *N7*-AFB<sub>1</sub>-Gua and AFB<sub>1</sub>-FAPy are similar, they alter the secondary DNA structure differently [242,253]. The increased chemical stability (persistence) and altered secondary DNA structure are believed to be responsible for the much greater mutagenicity of AFB<sub>1</sub>-FAPy compared to *N7*-AFB<sub>1</sub>-Gua. In fact, *N7*-AFB<sub>1</sub>-Gua and/or AFB<sub>1</sub>-FAPy cause primarily G to T mutations, consistent with the observed G to T mutations in codon 249 of the p53 tumor suppressor gene in 50% of hepatocellular carcinomas and in aflatoxin-treated human hepatocytes cultures [254,255]. Additionally, aflatoxin-induced G to T mutations in the *ras* oncogene are assumed to be important in tumor progression [256-258]. Although both *N7*-AFB<sub>1</sub>-Gua and AFB<sub>1</sub>-FAPy cause the types of mutation consistent with the ones observed in aflatoxin-exposed biological systems, the MF is 6-fold lower (4% vs 32%) for *N7*-AFB<sub>1</sub>-Gua compared to AFB<sub>1</sub>-FAPy, respectively [259,260]. Whether the *N7*-AFB<sub>1</sub>-Gua converted to AFB<sub>1</sub>-FAPy during the mutation assay was not determined, however, if this were the case, the mutagenic potency for the *N7*-AFB<sub>1</sub>-Gua would be even less, making the AFB<sub>1</sub>-FAPy even more important. This suggests that the AFB<sub>1</sub>-FAPy, and potentially other ring-opened *N7*-guanine adducts, may be the ultimate lesions responsible for mutagenesis and genotoxicity of aflatoxin and other carcinogens. Unfortunately, there are no data on the formation and persistence of other FAPy adducts and future investigations of *N7*-guanine adducts should include studies on the ring-opened FAPy derivatives.

## 5 Conclusions

After decades of research on *N7*-guanine adducts in animals and humans, it has become clear that specific *N7*-guanine adducts are excellent biomarkers for internal exposure when they are determined in tissue DNA. In contrast, *N7*-guanine adducts that can be formed from endogenous or background sources are less reliable for estimating low external exposures. While the presence of *N7*-guanine adducts clearly demonstrate exposure to the tissues or cells, subsequent interpretations and conclusions need to consider that the value of this endpoint is complicated by endogenous and background formation, and can vary according to species, age, duration of exposure, and tissue. From our review of the literature, we did not find any evidence that *N7*-guanine adducts can be used beyond confirmation of exposure to the target tissue and demonstration of the molecular dose. This is especially important for translation to human studies, since most studies consist of a single time point analysis of an individual adduct. If the goal is to confirm exposure or identify factors that increase endogenous formation, analysis of *N7*-guanine adducts in DNA may be sufficient. Consequently, values of *N7*-guanine adducts in human urine (not reviewed herein) may be sufficient to identify exposures or factors increasing endogenous formation between population groups, even if no information about the site of formation will be available [246,261,262]. Importantly, a correlation with other endpoints like chromosome aberrations or mutation frequency cannot be expected to be definitive, since such biomarkers of effect are not chemical-specific and are products of complex biological processes that may only partly (or even not at all) involve *N7*-guanine adducts.

The main challenge in studying the mutagenic potency of *N7*-guanine adducts is that their chemical instability has prevented systematic investigation of the lesions in site-directed mutagenesis studies. In fact, oligodeoxynucleotides containing *N7*-Me-Gua have been prepared, using DNA polymerase and structural analysis by NMR revealed no disturbance of the b-DNA helix [263]. However, since *N7*-guanine adducts are not considered stable enough to undergo site-directed mutagenesis studies, an alternative would be to stabilize the glycosidic bond by either substitution of guanine with 2-amino-8,9-dihydro-1H-purin-6(7H)-one or by incorporation of a fluorine at the 2'-position of the 2'-deoxyribose moiety as recently reported by Lee et al. [264]. The ring opened *N7*-Me-FAPy adduct of *N7*-Me-Gua have been shown to block DNA polymerase *in vitro* [265,266] but its relevance *in vivo* needs to be determined. Finally, the formation of *N7*-guanine adducts is often accompanied by formation of other adducts (*e.g.*, *O*<sup>6</sup>-Me-Gua) that are known to be highly mutagenic lesions. Mechanistically, the lack of mutagenicity is linked to the fact that the *N7*-position does not participate in hydrogen bonding in the DNA double helix, unlike the *N1*, *N*<sup>2</sup>, or *O*<sup>6</sup>-positions of Gua [2].

It is noteworthy that covalent binding to DNA and the ability to form *N7*-guanine adducts alone has long been considered evidence of genotoxicity for several drugs and chemicals [267]. Conversely, *N7*-guanine adducts easily depurinate to produce AP sites, however, these lesions are the most common endogenous DNA damage, and their number does not appear to increase even with extremely high exposures to alkylating agents. Therefore, one needs to be cautious in classifying compounds and drugs based on formation of *N7*-guanine adducts alone. This becomes very important for risk assessment of low chronic exposures, when data are limited to high and single dose exposures. The default is to assume a linear dose-response to zero and subsequent extrapolation of the DNA damage data from high to low dose. However, examples have been reported that show that at low exposures, biological processes like mutagenesis reach a background that is much different in slope than *N7*-guanine adducts [27,200]. It was suggested that these background mutations are driven by endogenous processes rather than by external exposure. For example, using [<sup>13</sup>C]MMS for cell treatment and mass spectrometry quantitation of [<sup>13</sup>C]*N7*-Me-Gua and *N7*-Me-Gua, Swenberg *et al.* demonstrated that the adduct formation by MMS from exogenous sources is linear towards zero, while the dose-response



for mutation frequency follows a “hockeystick” threshold dose-response (Figure 6)[27]. Similar data have also been presented for EO, EMS, and acrylamide [27,200,268]. Based on the information presented in Section 4, it is very unlikely that exposures resulting in elevated amounts of *N*7-guanine adducts are sufficient to induce mutations, since pro-mutagenic lesions, such as *O*<sup>6</sup>-guanine adducts, will also increase and are expected to drive mutagenesis.

A careful review of the literature related to *N*7-guanine adducts revealed that there is little evidence that *N*7-guanine adducts cause mutations. In addition, there is mounting evidence that they do not cause mutations, since they do not participate in hydrogen bonding and easily depurinate. In addition, formation of *N*7-guanine adducts is often accompanied by the formation of other adducts, known to be mutagenic, and therefore it is difficult to credit mutation events to *N*7-guanine adducts. As discussed in detail before, the relative ratio between *N*7-guanine adducts and other adducts (*e.g.*, *O*<sup>6</sup>-alkylguanine) is dependent upon the chemical and modified by species, strain, tissue, or cell types, differences in activation, and differences in DNA-repair. Consequently, the formation of *N*7-guanine adducts cannot be used in isolation as a quantitative biomarker for promutagenic DNA lesions, mutagenic response or as a surrogate for other biological processes.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

The authors are thankful to Lynn Pottenger for constructive and productive discussion and editorial assistance. This work was supported in part by NIH grants P42-ES05948, P30-ES10126, R01-ES012689 and the American Chemistry Council.

## References

1. Reiner B, Zamenhof S. Studies on the chemically reactive groups of deoxyribonucleic acids. *J Biol Chem* 1957;228:475–486. [PubMed: 13475333]
2. Watson JD, Crick FH. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. *Nature* 1953;171:737–738. [PubMed: 13054692]
3. Boysen G, Hecht SS. Analysis of DNA and protein adducts of benzo[*a*]pyrene in human tissues using structure-specific methods. *Mutat Res* 2003;543:17–30. [PubMed: 12510015]
4. van Zeeland AA. Molecular dosimetry of chemical mutagens. Relationship between DNA adduct formation and genetic changes analyzed at the molecular level. *Mutat Res* 1996;353:123–150. [PubMed: 8692189]
5. De Bont R, Van Larebeke N. Endogenous DNA damage in humans: a review of quantitative data. *Mutagenesis* 2004;19:169–185. [PubMed: 15123782]
6. Rundle A. Carcinogen-DNA adducts as a biomarker for cancer risk. *Mutat Res* 2006;600:23–36. [PubMed: 16824556]
7. Bartsch H. DNA adducts in human carcinogenesis: etiological relevance and structure-activity relationship. *Mutat Res* 1996;340:67–79. [PubMed: 8692183]
8. Beranek DT. Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. *Mutat Res* 1990;231:11–30. [PubMed: 2195323]
9. Pauwels W, Veulemans H. Comparison of ethylene, propylene and styrene 7,8-oxide in vitro adduct formation on N-terminal valine in human haemoglobin and on N-7-guanine in human DNA. *Mutat Res* 1998;418:21–33. [PubMed: 9748485]
10. Hemminki K. DNA adducts, mutations and cancer. *Carcinogenesis* 1993;14:2007–2012. [PubMed: 8222046]
11. Guengerich FP. Mechanisms of formation of DNA adducts from ethylene dihalides, vinyl halides, and arylamines. *Drug Metab Rev* 1994;26:47–66. [PubMed: 8082581]

12. La DK, Swenberg JA. DNA adducts: biological markers of exposure and potential applications to risk assessment. *Mutat Res* 1996;365:129–146. [PubMed: 8898994]
13. Swenberg JA, Ham A, Koc H, Morinello E, Ranasinghe A, Tretyakova N, Upton PB, Wu KY. DNA adducts: effects of low exposure to ethylene oxide, vinyl chloride and butadiene. *Mutat Res* 2000;464:77–86. [PubMed: 10633179]
14. Chang LW, Hsia SM, Chan PC, Hsieh LL. Macromolecular adducts: biomarkers for toxicity and carcinogenesis. *Annu Rev Pharmacol Toxicol* 1994;34:41–67. [PubMed: 8042856]
15. Doerge DR, da Costa GG, McDaniel LP, Churchwell MI, Twaddle NC, Beland FA. DNA adducts derived from administration of acrylamide and glycidamide to mice and rats. *Mutat Res* 2005;580:131–141. [PubMed: 15668115]
16. Doerge DR, Churchwell MI, Beland FA. Analysis of DNA adducts from chemical carcinogens and lipid peroxidation using liquid chromatography and electrospray mass spectrometry. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev* 2002;20:1–20. [PubMed: 12734050]
17. Miller EC, Miller JA. The presence and significance of bound aminoazo dyes in liver of rats fed p-dimethylaminoazobenzene. *Cancer Res* 1947;7:468–480.
18. Miller EC, Miller JA. In vivo combinations between carcinogens and tissue constituents and their possible role in carcinogenesis. *Cancer Res* 1952;12:547–556. [PubMed: 14945044]
19. Wheeler GP, Skipper HE. Studies with mustards. III. In vivo fixation of C14 from nitrogen mustard-C14H3 in nucleic acid fractions of animal tissues. *Arch Biochem Biophys* 1957;72:465–475. [PubMed: 13479130]
20. Brookes P, Lawley PD. The reaction of mono- and di-functional alkylating agents with nucleic acids. *Biochem J* 1961;80:496–503. [PubMed: 16748923]
21. Singer B, Grunberger D. *Molecular Biology of Mutagens and Carcinogens*, Plenum Press, New York, 1983
22. Swenson DH. Significance of electrophilic reactivity and especially DNA alkylation in carcinogenesis and mutagenesis. *Dev Toxicol Environ Sci* 1983;11:247–254. [PubMed: 6677460]
23. O'Connor PJ. Interaction of chemical carcinogens with macromolecules. *J Cancer Res Clin Oncol* 1981;99:167–186. [PubMed: 7251633]
24. Lawley PD. Some chemical aspects of dose-response relationships in alkylation mutagenesis. *Mutat Res* 1974;23:283–295. [PubMed: 4366872]
25. Singer B, Bodell WJ, Cleaver JE, Thomas GH, Rajewsky MF, Thon W. Oxygens in DNA are main targets for ethylnitrosourea in normal and xeroderma pigmentosum fibroblasts and fetal rat brain cells. *Nature* 1978;276:85–88. [PubMed: 740026]
26. Singer B. Reaction of guanosine with ethylating agents. *Biochemistry* 1972;11:3939–3947. [PubMed: 5079890]
27. Swenberg JA, Fryar-Tita E, Jeong YC, Boysen G, Starr T, Walker VE, Albertini RJ. Biomarkers in Toxicology and Risk Assessment: Informing Critical Dose-Response Relationships. *Chem Res Toxicol* 2008;21:253–265. [PubMed: 18161944]
28. Citti L, Gervasi PG, Turchi G, Bellucci G, Bianchini R. The reaction of 3,4-epoxy-1-butene with deoxyguanosine and DNA in vitro: synthesis and characterization of the main adducts. *Carcinogenesis* 1984;5:47–52. [PubMed: 6690085]
29. Margison GP, Margison JM, Montesano R. Methylated purines in the deoxyribonucleic acid of various Syrian-golden-hamster tissues after administration of a hepatocarcinogenic dose of dimethylnitrosamine. *Biochem J* 1976;157:627–634. [PubMed: 985411]
30. King HW, Osborne MR, Brookes P. The in vitro and in vivo reaction at the N7-position of guanine of the ultimate carcinogen derived from benzo(a)pyrene. *Chem Biol Interact* 1979;24:345–353. [PubMed: 428016]
31. Osborne M, Merrifield K. Depurination of benzo[a]pyrene-diolepoxide treated DNA. *Chem Biol Interact* 1985;53:183–195. [PubMed: 3922635]
32. Lewis JG, Swenberg JA. Differential repair of O(6)-methylguanine in DNA of rat hepatocytes and nonparenchymal cells. *Nature* 1980;288:185–41. [PubMed: 7432520]
33. Walker VE, Wu KY, Upton PB, Ranasinghe A, Scheller N, Cho MH, Vergnes JS, Skopek TR, Swenberg JA. Biomarkers of exposure and effect as indicators of potential carcinogenic risk arising

- from in vivo metabolism of ethylene to ethylene oxide. *Carcinogenesis* 2000;21:1661–1669. [PubMed: 10964097]
34. Young JF, Luecke RH, Doerge DR. Physiologically based pharmacokinetic/pharmacodynamic model for acrylamide and its metabolites in mice, rats, and humans. *Chem Res Toxicol* 2007;20:388–399. [PubMed: 17323977]
  35. Boucheron JA, Richardson FC, Morgan PH, Swenberg JA. Molecular dosimetry of O<sup>4</sup>-ethyldeoxythymidine in rats continuously exposed to diethylnitrosamine. *Cancer Res* 1987;47:1577–1581. [PubMed: 3815358]
  36. Kleihues P, Bucheler J. Long-term persistence of O<sup>6</sup>-methylguanine in rat brain DNA. *Nature* 1977;269:625–626. [PubMed: 917114]
  37. Gates KS, Nooner T, Dutta S. Biologically Relevant Chemical Reactions of N7-Alkylguanine Residues in DNA. *Chem Res Tox* 2004;17:839–856.
  38. Miller JA. Carcinogenesis by Chemicals: An Overview--G. H. A. Clowes Memorial Lecture. *Cancer Res* 1970;30:559–576. [PubMed: 4915745]
  39. Schwarz M, Wiesbeck G, Hummel J, Kunz W. Effect of ethanol on dimethylnitrosamine activation and DNA synthesis in rat liver. *Carcinogenesis* 1982;3:1071–1075. [PubMed: 7139864]
  40. Goth R, Rajewsky MF. Persistence of O<sup>6</sup>-ethylguanine in rat-brain DNA: correlation with nervous system-specific carcinogenesis by ethylnitrosourea. *Proc Natl Acad Sci U S A* 1974;71:639–643. [PubMed: 4522778]
  41. Kleihues P, Margison GP. Carcinogenicity of N-methyl-N-nitrosourea: possible role of excision repair of O<sup>6</sup>-methylguanine from DNA. *J Natl Cancer Inst* 1974;53:1839–1841. [PubMed: 4436874]
  42. Swenberg JA, Dyrhoff MC, Bedell MA, Popp JA, Huh N, Kirstein U, Rajewsky MF. O<sup>4</sup>-Ethyldeoxythymidine, but not O<sup>6</sup>-ethyldeoxyguanosine, accumulate in hepatocyte DNA of rats exposed continuously to diethylnitrosamine. *Proc Natl Acad Sci USA* 1984;81:1692–1695. [PubMed: 6584902]
  43. Gupta RC, Reddy MV, Randerath K. <sup>32</sup>P-postlabeling analysis of non-radioactive aromatic carcinogen--DNA adducts. *Carcinogenesis* 1982;3:1081–1092. [PubMed: 7139866]
  44. Randerath K, Randerath E, Agrawal HP, Gupta RC, Schurdak ME, Reddy MV. Postlabeling methods for carcinogen-DNA adduct analysis. *Environ Health Perspect* 1985;62:57–65. [PubMed: 3910421]
  45. Phillips DH. Detection of DNA modifications by the <sup>32</sup>P-postlabelling assay. *Mutat Res* 1997;378:1–12. [PubMed: 9288880]
  46. Savela K, Hemminki K, Hewer A, Phillips DH, Putman KL, Randerath K. Interlaboratory comparison of the <sup>32</sup>P-postlabelling assay for aromatic DNA adducts in white blood cells of iron foundry workers. *Mutat Res* 1989;224:485–492. [PubMed: 2586545]
  47. Arab K, Pedersen M, Nair J, Meerang M, Knudsen LE, Bartsch H. Typical signature of DNA damage in white blood cells: A pilot study on etheno adducts in Danish mother-newborn child pairs. *Carcinogenesis*. 2008
  48. Bartsch H, Nair J, Velic I. Etheno-DNA base adducts as tools in human cancer aetiology and chemoprevention. *Eur J Cancer Prev* 1997;6:529–534. [PubMed: 9496454]
  49. Nair J, Barbin A, Guichard Y, Bartsch H. 1,N<sup>6</sup>-ethenodeoxyadenosine and 3,N<sup>4</sup>-ethenodeoxycytine in liver DNA from humans and untreated rodents detected by immunoaffinity/<sup>32</sup>P-postlabeling. *Carcinogenesis* 1995;16:613–617. [PubMed: 7697821]
  50. Phillips DH, Arlt VM. The <sup>32</sup>P-postlabeling assay for DNA adducts. *Nat Protoc* 2007;2:2772–2781. [PubMed: 18007613]
  51. Boysen G, Kenney PM, Upadhyaya P, Wang M, Hecht SS. Effects of benzyl isothiocyanate and 2-phenethyl isothiocyanate on benzo[*a*]pyrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone metabolism in F-344 rats. *Carcinogenesis* 2003;24:517–525. [PubMed: 12663513]
  52. Foiles PG, Akerkar SA, Carmella SG, Kagan M, Stoner GD, Resau JH, Hecht SS. Mass spectrometric analysis of tobacco-specific nitrosamine-DNA adducts in smokers and nonsmokers. *Chem Res Tox* 1991;4:364–368.
  53. Lin D, Lay JO Jr, Bryant MS, Malaveille C, Friesen M, Bartsch H, Lang NP, Kadlubar FF. Analysis of 4-aminobiphenyl-DNA adducts in human urinary bladder and lung by alkaline hydrolysis and negative ion gas chromatography-mass spectrometry. *Environ Health Perspect* 1994;102:11–16. [PubMed: 7889831]

54. Melikian AA, Sun P, Coleman S, Amin S, Hecht SS. Detection of DNA and globin adducts of polynuclear aromatic hydrocarbon diol epoxides by gas chromatography-mass spectrometry and <sup>3</sup>H-CH<sub>3</sub>I postlabeling of released tetraols. *Chem Res Tox* 1996;9:508–516.
55. Fedtke N, Boucheron JA, Turner MJ, Swenberg JA. Vinyl chloride-induced DNA adducts. I: Quantitative determination of N<sup>2,3</sup>-ethenoguanine based on electrophore labeling. *Carcinogenesis* 1990;11:1279–1285. [PubMed: 2387013]
56. Pastorelli R, Cerri A, Mezzetti M, Consonni E, Airoidi L. Effect of DNA repair gene polymorphisms on BPDE-DNA Adducts in human lymphocytes. *Int J Cancer* 2002;100:9–13. [PubMed: 12115580]
57. Singh R, Farmer PB. Liquid chromatography-electrospray ionization-mass spectrometry: the future of DNA adduct detection. *Carcinogenesis* 2006;27:178–196. [PubMed: 16272169]
58. Esmans EL, Broes D, Hoes I, Lemiere F, Vanhoutte K. Liquid chromatography-mass spectrometry in nucleosid, nucleotide and modified nucleotide characterization. *J Chromatogr A* 1998;794:109–127.
59. Apruzzese WA, Vouros P. Analysis of DNA adducts by capillary methods coupled to mass spectrometry: a perspective. *J Chromatogr A* 1998;794:97–108. [PubMed: 9491559]
60. Andrews CL, Vouros P, Harsch A. Analysis of DNA adducts using high-performance separation techniques coupled to electrospray ionization mass spectrometry. *J Chromatogr A* 1999;856:515–526. [PubMed: 10526802]
61. Tarun M, Rusling JF. Quantitative Measurement of DNA Adducts Using Neutral Hydrolysis and LC-MS. Validation of Genotoxicity Sensors. *Analytical Chemistry* 2005;77:2056–2062. [PubMed: 15801738]
62. Koc H, Swenberg JA. Applications of mass spectrometry for quantitation of DNA adducts. *J Chromatogr B* 2002;778:323–343.
63. Farmer PB, Brown K, Tompkins E, Emms VL, Jones DJ, Singh R, Phillips DH. DNA adducts: Mass spectrometry methods and future prospects. *Toxicol Appl Pharmacol* 2005;207:293–301. [PubMed: 15990134]
64. Hah SS, Sumbad RA, Vere White RW, Turteltaub KW, Henderson PT. Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations. *Chem Res Toxicol* 2007;20:1745–1751. [PubMed: 18001055]
65. Brown K, Tompkins EM, Boocock DJ, Martin EA, Farmer PB, Turteltaub KW, Ubick E, Hemingway D, Horner-Glister E, White IN. Tamoxifen forms DNA adducts in human colon after administration of a single [14C]-labeled therapeutic dose. *Cancer Res* 2007;67:6995–7002. [PubMed: 17638912]
66. Vodicka P, Koskinen M, Vodickova L, Stetina R, Smerak P, Barta I, Hemminki K. DNA adducts, strand breaks and micronuclei in mice exposed to styrene by inhalation. *Chem Biol Interact* 2001;137:213–227. [PubMed: 11566290]
67. Belinsky SA, White CM, Devereux TR, Swenberg JA, Anderson MW. Cell selective alkylation of DNA in rat lung following low dose exposure to the tobacco specific carcinogen 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone. *Cancer Res* 1987;47:1143–1148. [PubMed: 3802095]
68. Koc H, Tretyakova NY, Walker VE, Henderson RF, Swenberg JA. Molecular dosimetry of N-7 guanine adduct formation in mice and rats exposed to 1,3-butadiene. *Chem Res Tox* 1999;12:566–574.
69. Belinsky SA, Dolan ME, White CM, Maronpot RR, Pegg AE, Anderson MW. Cell specific differences in O<sup>6</sup>-methylguanine-DNA methyltransferase activity and removal of O<sup>6</sup>-methylguanine in rat pulmonary cells. *Carcinogenesis* 1988;9:2053–2058. [PubMed: 3180342]
70. Gaubatz JW, Tan BH. Introduction, distribution, and removal of 7-methylguanine in different liver chromatin fractions of young and old mice. *Mutat Res* 1997;375:25–35. [PubMed: 9129677]
71. Park JW, Ames BN. 7-Methylguanine adducts in DNA are normally present at high levels and increase on aging: analysis by HPLC with electrochemical detection. *Proc Natl Acad Sci U S A* 1988;85:7467–7470. [PubMed: 3174647]
72. Druckrey H, Preussmann R. N-Nitroso-N-methylurethane: a potent carcinogen. *Nature* 1962;195:1111. [PubMed: 13887948]
73. Kleihues P, Lantos PL, Magee PN. Chemical carcinogenesis in the nervous system. *Int Rev Exp Pathol* 1976;15:153–232. [PubMed: 176123]

74. IARC. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans: some N-nitroso compounds. IARC Monogr Eval Carcinog Risk Chem Man 1978;17:1–349. [PubMed: 150392]
75. Buecheler J, Kleihues P. Excision of O<sup>6</sup>-methylguanine from DNA of various mouse tissues following a single injection of N-methyl-N-nitrosourea. Chem Biol Interact 1977;16:325–333. [PubMed: 862133]
76. Margison GP, Kleihues P. Chemical carcinogenesis in the nervous system. Preferential accumulation of O<sup>6</sup>-methylguanine in rat brain deoxyribonucleic acid during repetitive administration of N-methyl-N-nitrosourea. Biochem J 1975;148:521–525. [PubMed: 1200992]
77. Wechsler W, Rice JM, Vesselinovitch SD. Transplacental and neonatal induction of neurogenic tumors in mice: comparison with related species and with human pediatric neoplasms. Natl Cancer Inst Monogr 1979;219–226. [PubMed: 384262]
78. Swenberg JA. Current approaches to the experimental investigation of chemicals in relation to cancer of the brain. Ann N Y Acad Sci 1982;381:43–53. [PubMed: 6953800]
79. Singer B. Alkylation of the O<sup>6</sup> of guanine is only one of many chemical events that may initiate carcinogenesis. Cancer Invest 1984;2:233–238. [PubMed: 6733566]
80. Engelbergs J, Thomale J, Rajewsky MF. Role of DNA repair in carcinogen-induced ras mutation. Mutat Res 2000;450:139–153. [PubMed: 10838139]
81. Magee PN, Barnes JM. The production of malignant primary hepatic tumours in the rat by feeding dimethylnitrosamine. Br J Cancer 1956;10:114–122. [PubMed: 13342328]
82. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Tox 1998;11:559–603.
83. Hecht SS. Progress and challenges in selected areas of tobacco carcinogenesis. Chem Res Tox 2008;21:160–171.
84. Shuker DE, Bartsch H. DNA adducts of nitrosamines. IARC Sci Publ 1994:73–89. [PubMed: 7806342]
85. Morse MA, Eklind KI, Hecht SS, Chung FL. Inhibition of tobacco-specific nitrosamine 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK) tumorigenesis with aromatic isothiocyanates. IARC Sci Publ 1991:529–534. [PubMed: 1855911]
86. Olajos EJ. Biological interactions of N-nitroso compounds: A review. Ecotoxicology and Environmental Safety 1977;1:175–196. [PubMed: 361370]
87. Preussmann R. Carcinogenic N-nitroso compounds and their environmental significance. Naturwissenschaften 1984;71:25–30. [PubMed: 6371547]
88. Lindamood C III, Bedell MA, Billings KC, Dyroff MC, Swenberg JA. Dose response for DNA alkylation, [3H]thymidine uptake into DNA, and O<sup>6</sup>-methylguanine-DNA methyltransferase activity in hepatocytes of rats and mice continuously exposed to dimethylnitrosamine. Cancer Res 1984;44:196–200. [PubMed: 6690035]
89. Pegg AE, Hui G. Formation and subsequent removal of O<sup>6</sup>-methylguanine from deoxyribonucleic acid in rat liver and kidney after small doses of dimethylnitrosamine. Biochem J 1978;173:739–748. [PubMed: 708371]
90. Zang H, Fang Q, Pegg AE, Guengerich FP. Kinetic Analysis of Steps in the Repair of Damaged DNA by Human O<sup>6</sup>-Alkylguanine-DNA Alkyltransferase. J Biol Chem 2005;280:30873–30881. [PubMed: 16000301]
91. Jalas JR, Hecht SS, Murphy SE. Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. Chem Res Toxicol 2005;18:95–110. [PubMed: 15720112]
92. Upadhyaya P, Kalscheuer S, Hochalter JB, Villalta PW, Hecht SS. Quantitation of pyridylhydroxybutyl-DNA adducts in liver and lung of F-344 rats treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and enantiomers of its metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Chem Res Toxicol 2008;21:1468–1476. [PubMed: 18570389]
93. Upadhyaya P, Sturla SJ, Tretyakova N, Ziegel R, Villalta PW, Wang M, Hecht SS. Identification of Adducts Produced by the Reaction of 4-(Acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanol with Deoxyguanosine and DNA. Chem Res Tox 2003;16:180–190.

94. Castonguay A, Foiles PG, Trushin N, Hecht SS. Study of DNA methylation by tobacco-specific *N*-nitrosamines. *Environ Health Perspect* 1985;62:197–202. [PubMed: 4085424]
95. Devereux TR, Anderson MW, Belinsky SA. Factors regulating activation and DNA alkylation by 4-(*N*-methyl-*N*-nitrosamino)-1-(3-pyridyl)-1-butanone and nitrosodimethylamine in rat lung and isolated lung cells, and the relationship to carcinogenicity. *Cancer Res* 1988;48:4215–4221. [PubMed: 3390815]
96. Foiles PG, Trushin N, Castonguay A. Measurement of O<sup>6</sup>-methyldeoxyguanosine in DNA methylated by the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone using a biotin-avidin enzyme-linked immunosorbent assay. *Carcinogenesis* 1985;6:989–993. [PubMed: 4017179]
97. Guo Z, Smith TJ, Thomas PE, Yang CS. Metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone as measured by DNA alkylation in vitro and its inhibition by isothiocyanates. *Cancer Res* 1991;51:4798–4803. [PubMed: 1893372]
98. Murphy SE, Heiblum R, Trushin N. Comparative metabolism of *N'*-nitrosonornicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by cultured F344 rat oral tissue and esophagus. *Cancer Res* 1990;50:4685–4691. [PubMed: 2369743]
99. Sticha KR, Staretz ME, Wang M, Liang H, Kenney PM, Hecht SS. Effects of benzyl isothiocyanate and phenethyl isothiocyanate on benzo[*a*]pyrene metabolism and DNA adduct formation in the *A/J* mouse. *Carcinogenesis* 2000;21:1711–1719. [PubMed: 10964103]
100. Sticha KR, Kenney PM, Boysen G, Liang H, Su X, Wang M, Upadhyaya P, Hecht SS. Effects of benzyl isothiocyanate and phenethyl isothiocyanate on DNA adduct formation by a mixture of benzo[*a*]pyrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in *A/J* mouse lung. *Carcinogenesis* 2002;23:1433–1439. [PubMed: 12189184]
101. Hecht SS. DNA adduct formation from tobacco-specific *N*-nitrosamines. *Mutat Res* 1999;424:127–142. [PubMed: 10064856]
102. Murphy SE, Palomino A, Hecht SS, Hoffmann D. Dose-response study of DNA and hemoglobin adduct formation by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in F344 rats. *Cancer Res* 1990;50:5446–5452. [PubMed: 2386949]
103. Belinsky SA, White CM, Trushin N, Hecht SS. Cell specificity for the pulmonary metabolism of tobacco-specific nitrosamines in the Fischer rat. *Carcinogenesis* 1989;10:2269–2274. [PubMed: 2591016]
104. Belinsky SA, Foley JF, White CM, Anderson MW, Maronpot RR. Dose-response relationship between O<sup>6</sup>-methylguanine formation in Clara cells and induction of pulmonary neoplasia in the rat by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. *Cancer Res* 1990;50:3772–3780. [PubMed: 2340522]
105. IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Solar and ultraviolet radiation. *IARC Monogr Eval Carcinog Risks Hum* 1992;55:1–316. [PubMed: 1345607]
106. Toth B. Synthetic and naturally occurring hydrazines as possible cancer causative agents. *Cancer Res* 1975;35:3693–3697. [PubMed: 1238167]
107. NTP. Hydrazine and hydrazine sulfate. *Rep Carcinog* 2002;10:138–139. [PubMed: 15326661]
108. Jenner AM, Timbrell JA. In vitro microsomal metabolism of hydrazine. *Xenobiotica* 1995;25:599–609. [PubMed: 7483660]
109. Herron DC, Shank RC. DNA methylation during chronic administration of 1,2-dimethylhydrazine in a carcinogenic regimen. *Carcinogenesis* 1982;3:857–860. [PubMed: 7127668]
110. Harbach PR, Swenberg JA. Effects of selenium on 1,2-dimethylhydrazine metabolism and DNA alkylation. *Carcinogenesis* 1981;2:575–580. [PubMed: 7273336]
111. Swenberg JA, Cooper HK, Bucheler J, Kleihues P. 1,2-Dimethylhydrazine-induced methylation of DNA bases in various rat organs and the effect of pretreatment with disulfiram. *Cancer Res* 1979;39:465–467. [PubMed: 761218]
112. Swenberg JA, Richardson FC, Boucheron JA, Dyroff MC. Relationships between DNA adduct formation and carcinogenesis. *Environ Health Perspect* 1985;62:177–183. [PubMed: 4085420]
113. Herron DC, Shank RC. In vivo kinetics of O<sup>6</sup>-methylguanine and 7-methylguanine formation and persistence in DNA of rats treated with symmetrical dimethylhydrazine. *Cancer Res* 1981;41:3967–3972. [PubMed: 7285005]

114. Pegg AE. Repair of alkylated DNA by cell extracts from various organs and species. *Basic Life Sci* 1983;24:545–563. [PubMed: 6860275]
115. Bedell MA, Lewis JG, Billings KC, Swenberg JA. Cell specificity in hepatocarcinogenesis: preferential accumulation of O<sup>6</sup>-methylguanine in target cell DNA during continuous exposure to rats to 1,2-dimethylhydrazine. *Cancer Res* 1982;42:3079–3083. [PubMed: 7093953]
116. Druckrey H, Preussmann R, Matzkies F, Ivankovic S. [Selective production of intestinal cancer in rats by 1,2-dimethylhydrazine]. *Naturwissenschaften* 1967;54:285–286. [PubMed: 5589923]
117. Delaney V, Mullaney J, Bourke E. Juvenile nephronophthisis, congenital hepatic fibrosis and retinal hypoplasia in twins. *Q J Med* 1978;47:281–290. [PubMed: 568809]
118. Weisburger JH, Madison RM, Ward JM, Viguera C, Weisburger EK. Modification of diethylnitrosamine liver carcinogenesis with phenobarbital but not with immunosuppression. *J Natl Cancer Inst* 1975;54:1185–1188. [PubMed: 165310]
119. Swenberg JA, Bedell MA, Billings KC, Umbenhauer DR, Pegg AE. Cell-specific differences in O<sup>6</sup>-alkylguanine DNA repair activity during continuous exposure to carcinogen. *Proc Natl Acad Sci USA* 1982;79:5499–5502. [PubMed: 6957878]
120. IARC. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans: 1,3-Butadiene (in preparation). *IARC Monogr Eval Carcinog Risk Chem Man* 2007;97
121. Cheng H, Sathiakumar N, Graff J, Matthews R, Delzell E. 1,3-Butadiene and leukemia among synthetic rubber industry workers: exposure-response relationships. *Chem Biol Interact* 2007;166:15–24. [PubMed: 17123495]
122. Delzell E, Sathiakumar N, Graff J, Macaluso M, Maldonado G, Matthews R. An updated study of mortality among North American synthetic rubber industry workers. *HEI Report* 2006:1–63.
123. Sathiakumar N, Delzell E, Cheng H, Lynch J, Sparks W, Macaluso M. Validation of 1,3-butadiene exposure estimates for workers at a synthetic rubber plant. *Chem Biol Interact* 2007;166:29–43. [PubMed: 17097078]
124. Divine BJ, Hartman CM. A cohort mortality study among workers at a 1,3 butadiene facility. *Chem Biol Interact* 2001;135-136:535–553. [PubMed: 11397411]
125. Koskinen M, Plna K. Specific DNA adducts induced by some mono-substituted epoxides in vitro and in vivo. *Chem Biol Interact* 2000;129:209–229. [PubMed: 11137062]
126. Rios-Blanco MN, Ranasinghe A, Upton P, Lee MS, Filser JG, Swenberg JA. Exposure-dependent accumulation of *N*-(2-hydroxypropyl)valine in hemoglobin of F344 rats exposed to propylene oxide by the inhalation route. *Journal of Chromatography B* 2002;778:383–391.
127. Rios-Blanco MN, Ranasinghe A, Lee MS, Faller T, Filser JG, Swenberg JA. Molecular dosimetry of *N*7-(2-hydroxypropyl)guanine in tissues of F344 rats after inhalation exposure to propylene oxide. *Carcinogenesis* 2003;24:1233–1238. [PubMed: 12807731]
128. Wu KY, Scheller N, Ranasinghe A, Yen TY, Sangaiah R, Giese R, Swenberg JA. A gas chromatography/electron capture/negative chemical ionization high-resolution mass spectrometry method for analysis of endogenous and exogenous *N*7-(2-hydroxyethyl)guanine in rodents and its potential for human biological monitoring. *Chem Res Toxicol* 1999;12:722–729. [PubMed: 10458706]
129. Rusyn I, Asakura S, Li Y, Kosyk O, Koc H, Nakamura J, Upton PB, Swenberg JA. Effects of ethylene oxide and ethylene inhalation on DNA adducts, apurinic/apyrimidinic sites and expression of base excision DNA repair genes in rat brain, spleen, and liver. *DNA Repair* 2005;4:1099–1110. [PubMed: 16051529]
130. Bolt HM, Filser JG. Kinetics and disposition in toxicology. Example: Carcinogenic risk estimate for ethylene. *Arch Toxicol* 1987;60:73–76. [PubMed: 3619647]
131. Bolt HM, Filser JG, Stormer F. Inhalation pharmacokinetics based on gas uptake studies. V. Comparative pharmacokinetics of ethylene and 1,3-butadiene in rats. *Arch Toxicol* 1984;55:213–218. [PubMed: 6517696]
132. Föst U, Marczyński B, Kasemann R, Peter H. Determination of 7-(2-hydroxyethyl)guanine with gas chromatography/mass spectrometry as a parameter for genotoxicity of ethylene oxide. *Arch Toxicol* 1989;250–253. [PubMed: 2764715]
133. Walker VE, Fennell TR, Upton PB, Skopek TR, Prevost V, Shuker DE, Swenberg JA. Molecular dosimetry of ethylene oxide: formation and persistence of 7-(2-hydroxyethyl)guanine in DNA

- following repeated exposures of rats and mice. *Cancer Res* 1992;52:4328–4334. [PubMed: 1643630]
134. Walker VE, Fennell TR, Upton PB, MacNeela JP, Swenberg JA. Molecular dosimetry of DNA and hemoglobin adducts in mice and rats exposed to ethylene oxide. *Environ Health Perspect* 1993;99:11–17. [PubMed: 8319608]
135. Filser JG, Denk B, Törnqvist M, Kessler W, Ehrenberg L. Pharmacokinetics of ethylene in man: body burden with ethylene oxide and hydroxyethylation of hemoglobin due to endogenous and environmental ethylene. *Arch Toxicol* 1992;66:157–163. [PubMed: 1303633]
136. Filser JG, Bolt HM. Exhalation of ethylene oxide by rats on exposure to ethylene. *Mutat Res* 1983;120:57–60. [PubMed: 6835263]
137. Jensen KG. Determination of ethylene oxide residues in processed food products by gas-liquid chromatography after derivatization. *Z Lebensm Unters Forsch* 1988;187:535–540. [PubMed: 3223093]
138. Tompkins EM, Jones DJ, Lamb JH, Marsden DA, Farmer PB, Brown K. Simultaneous detection of five different 2-hydroxyethyl-DNA adducts formed by ethylene oxide exposure, using a high-performance liquid chromatography/electrospray ionisation tandem mass spectrometry assay. *Rapid Commun Mass Spectrom* 2008;22:19–28. [PubMed: 18041793]
139. Marsden DA, Jones DJ, Lamb JH, Tompkins EM, Farmer PB, Brown K. Determination of endogenous and exogenously derived N7-(2-hydroxyethyl)guanine adducts in ethylene oxide-treated rats. *Chem Res Toxicol* 2007;20:290–299. [PubMed: 17263564]
140. van Sittert NJ, Boogaard PJ, Natarajan AT, Bates AD, Ehrenberg LG, Tornqvist MA. Formation of DNA adducts and induction of mutagenic effects in rats following 4 weeks inhalation exposure to ethylene oxide as a basis for cancer risk assessment. *Mutat Res* 2000;447:27–48. [PubMed: 10686305]
141. Bolt HM, Leutbecher M, Golka K. A note on the physiological background of the ethylene oxide adduct 7-(2-hydroxyethyl)guanine in DNA from human blood. *Arch Toxicol* 1997;71:719–721. [PubMed: 9363847]
142. Kato S, Petruzzelli S, Bowman ED, Turteltaub KW, Blomeke B, Weston A, Shields PG. 7-Alkyldeoxyguanosine adduct detection by two-step HPLC and the <sup>32</sup>P-postlabeling assay. *Carcinogenesis* 1993;14:545–550. [PubMed: 8386066]
143. Yong LC, Schulte PA, Kao CY, Giese RW, Boeniger MF, Strauss GH, Petersen MR, Wiencke JK. DNA adducts in granulocytes of hospital workers exposed to ethylene oxide. *Am J Ind Med* 2007;50:293–302. [PubMed: 17354254]
144. Törnqvist M, Magnusson AL, Farmer PB, Tang YS, Jeffrey AM, Wazneh L, Beulink GD, van der WH, van Sittert NJ. Ring test for low levels of N-(2-hydroxyethyl)valine in human hemoglobin. *Anal Biochem* 1992;203:357–360. [PubMed: 1416033]
145. Wu KY, Chiang SY, Huang TH, Tseng YS, Chen YL, Kuo HW, Hsieh CL. Formation of N-(2-hydroxyethyl)valine in human hemoglobin-effect of lifestyle factors. *Mutat Res* 2004;559:73–82. [PubMed: 15066576]
146. Zhao C, Tyndyk M, Eide I, Hemminki K. Endogenous and background DNA adducts by methylating and 2-hydroxyethylating agents. *Mutat Res* 1999;424:117–125. [PubMed: 10064855]
147. Zhao CY, Kumar R, Zahlsen K, Sundmark HB, Hemminki K, Eide I. Persistence of 7-(2-hydroxyethyl)guanine-DNA adducts in rats exposed to ethene by inhalation. *Biomarkers* 1997;2:355–359.
148. Widlak P, Zheng X, Österdahl BG, Drettner B, Christensson B, Kumar R, Hemminki K. N-nitrosodimethylamine and 7-methylguanine DNA adducts in tissues of rats fed Chinese salted fish. *Cancer Lett* 1995;94:85–90. [PubMed: 7621449]
149. Pottenger LH, Malley LA, Bogdanffy MS, Donner EM, Upton PB, Li Y, Walker VE, Harkema JR, Banton MI, Swenberg JA. Evaluation of effects from repeated inhalation exposure of F344 rats to high concentrations of propylene. *Toxicol Sci* 2007;97:336–347. [PubMed: 17341482]
150. Himmelstein MW, Acquavella JF, Recio L, Medinsky MA, Bond JA. Toxicology and epidemiology of 1,3-butadiene. *Crit Rev Toxicol* 1997;27:1–108. [PubMed: 9115622]



151. Csanady GA, Guengerich FP, Bond JA. Comparison of the biotransformation of 1,3-butadiene and its metabolite, butadiene monoepoxide, by hepatic and pulmonary tissues from humans, rats and mice. *Carcinogenesis* 1992;13:1143–1153. [PubMed: 1638680]
152. Duescher RJ, Elfarrar AA. Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: evidence for major roles by cytochromes P450 2A6 and 2E1. *Arch Biochem Biophys* 1994;311:342–349. [PubMed: 8203896]
153. Zhao CY, Koskinen M, Hemminki K. <sup>32</sup>P-postlabelling analysis of 1,3-butadiene-induced DNA adducts in vivo and in vitro. *Biomarkers* 2000;5:168–181.
154. Tretyakova N, Sangaiah R, Yen TY, Gold A, Swenberg JA. Adenine adducts with diepoxybutane: isolation and analysis in exposed calf thymus DNA. *Chem Res Tox* 1997;10:1171–1179.
155. Tretyakova N, Lin Y, Sangaiah R, Upton PB, Swenberg JA. Identification and quantitation of DNA adducts from calf thymus DNA exposed to 3,4-epoxy-1-butene. *Carcinogenesis* 1997;18:137–147. [PubMed: 9054600]
156. Kanuri M, Nechev LV, Tamura PJ, Harris CM, Harris TM, Lloyd RS. Mutagenic spectrum of butadiene-derived N1-deoxyinosine adducts and N6,N6-deoxyadenosine intrastrand cross-links in Mammalian cells. *Chem Res Tox* 2002;15:1572–1580.
157. Rodriguez DA, Kowalczyk A, Ward JB Jr, Harris CM, Harris TM, Lloyd RS. Point mutations induced by 1,2-epoxy-3-butene N1 deoxyinosine adducts. *Environ Mol Mutagen* 2001;38:292–296. [PubMed: 11774359]
158. Carmical JR, Nechev LV, Harris CM, Harris TM, Lloyd RS. Mutagenic potential of adenine N<sup>6</sup> adducts of monoepoxide and diepoxy derivatives of butadiene. *Environ Mol Mutagen* 2000;35:48–56. [PubMed: 10692227]
159. Krause RJ, Elfarrar AA. Oxidation of butadiene monoxide to meso- and (+/-)-diepoxybutane by cDNA-expressed human cytochrome P450s and by mouse, rat, and human liver microsomes: evidence for preferential hydration of meso-diepoxybutane in rat and human liver microsomes. *Arch Biochem Biophys* 1997;337:176–184. [PubMed: 9016811]
160. Goggin M, Anderson C, Park S, Swenberg J, Walker V, Tretyakova N. Quantitative high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry analysis of the adenine-guanine cross-links of 1,2,3,4-diepoxybutane in tissues of butadiene-exposed B6C3F1 mice. *Chem Res Toxicol* 2008;21:1163–1170. [PubMed: 18442269]
161. Goggin M, Loeber R, Park S, Walker V, Wickliffe J, Tretyakova N. HPLC-ESI+-MS/MS analysis of N7-guanine-N7-guanine DNA cross-links in tissues of mice exposed to 1,3-butadiene. *Chem Res Toxicol* 2007;20:839–847. [PubMed: 17455958]
162. Tretyakova N, Livshits A, Park S, Bisht B, Goggin M. Structural elucidation of a novel DNA-DNA cross-link of 1,2,3,4-diepoxybutane. *Chem Res Toxicol* 2007;20:284–289. [PubMed: 17305410]
163. Loeber R, Michaelson E, Fang Q, Campbell C, Pegg AE, Tretyakova N. Cross-linking of the DNA repair protein O(6)-alkylguanine DNA alkyltransferase to DNA in the presence of antitumor nitrogen mustards. *Chem Res Toxicol* 2008;21:787–795. [PubMed: 18324787]
164. Loeber R, Rajesh M, Fang Q, Pegg AE, Tretyakova N. Cross-linking of the human DNA repair protein O6-alkylguanine DNA alkyltransferase to DNA in the presence of 1,2,3,4-diepoxybutane. *Chem Res Toxicol* 2006;19:645–654. [PubMed: 16696566]
165. Goggin M, Swenberg JA, Walker VE, Tretyakova N. Molecular dosimetry of 1,2,3,4-diepoxybutane-induced DNA-DNA cross-links in B6C3F1 mice and F344 rats exposed to 1,3-butadiene by inhalation. *Cancer Res* 2009;69:2479–2486. [PubMed: 19276346]
166. Bechtold WE, Strunk MR, Chang IY, Ward JB, Henderson RF. Species-Differences in Urinary Butadiene Metabolites - Comparisons of Metabolite Ratios Between Mice, Rats, and Humans. *Toxicology and Applied Pharmacology* 1994;127:44–49. [PubMed: 8048052]
167. Cheng X, Ruth JA. A simplified methodology for quantitation of butadiene metabolites. Application to the study of 1,3-butadiene metabolism by rat liver microsomes. *Drug Metab Dispos* 1993;21:121–124. [PubMed: 8095204]
168. Kreuzer PE, Kessler W, Welter HF, Baur C, Filser JG. Enzyme specific kinetics of 1,2-epoxybutene-3 in microsomes and cytosol from livers of mouse, rat, and man. *Arch Toxicol* 1991;65:59–67. [PubMed: 2043052]

169. Nauhaus SK, Fennell TR, Asgharian B, Bond JA, Sumner SC. Characterization of urinary metabolites from Sprague-Dawley rats and B6C3F1 mice exposed to [1,2,3,4-<sup>13</sup>C]butadiene. *Chem Res Toxicol* 1996;9:764–773. [PubMed: 8831821]
170. Sabourin PJ, Burka LT, Bechtold WE, Dahl AR, Hoover MD, Chang LY, Henderson RF. Species differences in urinary butadiene metabolites; identification of 1,2-dihydroxy-4-(N-acetylcysteinyl) butane, a novel metabolite of butadiene. *Carcinogenesis* 1992;13:1633–1638. [PubMed: 1394848]
171. Malvoisin E, Roberfroid M. Hepatic microsomal metabolism of 1,3-butadiene. *Xenobiotica* 1982;12:137–144. [PubMed: 7090423]
172. Lewis DF, Bird MG, Parke DV. Molecular modelling of CYP2E1 enzymes from rat, mouse and man: an explanation for species differences in butadiene metabolism and potential carcinogenicity, and rationalization of CYP2E substrate specificity. *Toxicology* 1997;118:93–113. [PubMed: 9129165]
173. Boysen G, Georgieva NI, Upton PB, Jayaraj K, Li Y, Walker VE, Swenberg JA. Analysis of diepoxide-specific cyclic N-terminal globin adducts in mice and rats after inhalation exposure to 1,3-butadiene. *Cancer Res* 2004;64:8517–8520. [PubMed: 15574756]
174. Boysen G, Georgieva NI, Upton PB, Walker VE, Swenberg JA. N-terminal globin adducts as biomarkers for formation of butadiene derived epoxides. *Chem Biol Interact* 2007;166:84–92. [PubMed: 17084829]
175. Boysen G, Scarlett CO, Temple B, Combs TP, Brooks NL, Borchers CH, Swenberg JA. Identification of covalent modifications in P450 2E1 by 1,2-epoxy-3-butene in vitro. *Chem Biol Interact* 2007;166:170–175. [PubMed: 17298833]
176. Blobaum AL, Kent UM, Alworth WL, Hollenberg PF. Mechanism-based inactivation of cytochromes P450 2E1 and 2E1 T303A by tert-butyl acetylenes: characterization of reactive intermediate adducts to the heme and apoprotein. *Chem Res Toxicol* 2002;15:1561–1571. [PubMed: 12482238]
177. von Weyarn LB, Sridar C, Hollenberg PF. Identification of amino acid residues involved in the inactivation of cytochrome P450 2B1 by two acetylenic compounds: the role of three residues in nonsubstrate recognition Sites. *J Pharmacol Exp Ther* 2004;311:71–79. [PubMed: 15178696]
178. von Weyarn LB, Blobaum AL, Hollenberg PF. The mechanism-based inactivation of P450 2B4 by tert-butyl 1-methyl-2-propynyl ether: structural determination of the adducts to the P450 heme. *Archives of Biochemistry and Biophysics* 2004;425:95–105. [PubMed: 15081898]
179. Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. *Curr Drug Metab* 2008;9:384–394. [PubMed: 18537575]
180. Correia MA. Cytochrome P450 turnover. *Methods Enzymol* 1991;206:315–325. [PubMed: 1784218]
181. Kartha JS, Yost GS. Mechanism-based inactivation of lung-selective cytochrome P450 CYP2F enzymes. *Drug Metab Dispos* 2008;36:155–162. [PubMed: 17962375]
182. Moreno RL, Goosen T, Kent UM, Chung FL, Hollenberg PF. Differential effects of naturally occurring isothiocyanates on the activities of cytochrome P450 2E1 and the mutant P450 2E1 T303A. *Arch Biochem Biophys* 2001;391:99–110. [PubMed: 11414690]
183. Ortiz de Montellano PR, Mico BA. Destruction of cytochrome P-450 by ethylene and other olefins. *Mol Pharmacol* 1980;18:128–135. [PubMed: 7412756]
184. Ortiz de Montellano PR, Kunze KL, Mico BA. Destruction of cytochrome P-450 by olefins: N-alkylation of prosthetic heme. *Mol Pharmacol* 1980;18:602–605. [PubMed: 7464822]
185. Ortiz de Montellano PR, Beilan HS, Kunze KL, Mico BA. Destruction of cytochrome P-450 by ethylene. Structure of the resulting prosthetic heme adduct. *J Biol Chem* 1981;256:4395–4399. [PubMed: 7217086]
186. Masubuchi Y, Horie T. Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. *Crit Rev Toxicol* 2007;37:389–412. [PubMed: 17612953]
187. Harrison KL, Khan NS, Dey P, Povey AC. N7-methyldeoxyguanosine levels in DNA isolated from cervical cytology samples are associated with smoking. *Int J Cancer* 2006;119:961–963. [PubMed: 16557591]

188. Zhao C, Hemminki K. The in vivo levels of DNA alkylation products in human lymphocytes are not age dependent: an assay of 7-methyl- and 7-(2-hydroxyethyl)-guanine DNA adducts. *Carcinogenesis* 2002;23:307–310. [PubMed: 11872637]
189. Mustonen R, Hemminki K. 7-Methylguanine levels in DNA of smokers' and non-smokers' total white blood cells, granulocytes and lymphocytes. *Carcinogenesis* 1992;13:1951–1955. [PubMed: 1423861]
190. Mustonen R, Schoket B, Hemminki K. Smoking-related DNA adducts: <sup>32</sup>P-postlabeling analysis of 7-methylguanine in human bronchial and lymphocyte DNA. *Carcinogenesis* 1993;14:151–154. [PubMed: 8425264]
191. Mustonen R, Forsti A, Hietanen P, Hemminki K. Measurement by <sup>32</sup>P-postlabelling of 7-methylguanine levels in white blood cell DNA of healthy individuals and cancer patients treated with dacarbazine and procarbazine. Human data and method development for 7-alkylguanines. *Carcinogenesis* 1991;12:1423–1431. [PubMed: 1860163]
192. Harrison KL, Wood M, Lees NP, Hall CN, Margison GP, Povey AC. Development and application of a sensitive and rapid immunoassay for the quantitation of N7-methyldeoxyguanosine in DNA samples. *Chem Res Toxicol* 2001;14:295–301. [PubMed: 11258978]
193. Harrison KL, Crosbie PA, Agius RM, Barber PV, Carus M, Margison GP, Povey AC. No association between N7-methyldeoxyguanosine and 8-oxodeoxyguanosine levels in human lymphocyte DNA. *Mutat Res* 2006;600:125–130. [PubMed: 16765387]
194. Saad AA, O'Connor PJ, Mostafa MH, Metwalli NE, Cooper DP, Margison GP, Povey AC. Bladder tumor contains higher N7-methylguanine levels in DNA than adjacent normal bladder epithelium. *Cancer Epidemiol Biomarkers Prev* 2006;15:740–743. [PubMed: 16614117]
195. Lewis SJ, Cherry NM, Niven RM, Barber PV, Povey AC. Associations between smoking, GST genotypes and N7-methylguanine levels in DNA extracted from bronchial lavage cells. *Mutat Res* 2004;559:11–18. [PubMed: 15066569]
196. Szyfter K, Hemminki K, Szyfter W, Szmeja Z, Banaszewski J, Pabiszczak M. Tobacco smoke-associated N<sup>7</sup>-alkylguanine in DNA of larynx tissue and leucocytes. *Carcinogenesis* 1996;17:501–506. [PubMed: 8631136]
197. Filser JG, Denk B, Tornqvist M, Kessler W, Ehrenberg L. Pharmacokinetics of ethylene in man; body burden with ethylene oxide and hydroxyethylation of hemoglobin due to endogenous and environmental ethylene. *Arch Toxicol* 1992;66:157–163. [PubMed: 1303633]
198. Törnqvist M, Mowrer J, Jensen S, Ehrenberg L. Monitoring of environmental cancer initiators through hemoglobin adducts by a modified Edman degradation method. *Analytical Biochemistry* 1986;154:255–266. [PubMed: 3706730]
199. Törnqvist M, Almberg JG, Bergmark E, Nilsson S, Osterman-Golkar SM. Ethylene oxide doses in ethene-exposed fruit store workers. *Scandinavian Journal of Work & Environmental Health* 1989;15:436–438.
200. Tompkins EM, McLukie KIE, Jones DJL, Farmer PB, Brown K. Mutagenicity of DNA adducts derived from ethylene oxide exposure in the pSP189 shuttle vector replicated in human Ad293 cells. *Mutat Res*. 2009
201. Lieberman M, Kunishi A, Mapson LW, Wardale DA. Stimulation of Ethylene Production in Apple Tissue Slices by Methionine. *Plant Physiol* 1966;41:376–382. [PubMed: 16656267]
202. Baker JE, Anderson JD, Adams DO, Apfelbaum A, Lieberman M. Biosynthesis of ethylene from methionine in aminoethoxyvinylglycine-resistant avocado tissue. *Plant Physiol* 1982;69:93–97. [PubMed: 16662192]
203. Swenberg JA, Koc H, Upton PB, Georgieva N, Ranasinghe A, Walker VE, Henderson R. Using DNA and hemoglobin adducts to improve the risk assessment of butadiene. *Chem Biol Interact* 2001;135-136:387–403. [PubMed: 11397403]
204. Tornqvist M, Kautiainen A. Adducted proteins for identification of endogenous electrophiles. *Environ Health Perspect* 1993;99:39–44. [PubMed: 8319656]
205. Beranek DT, Heflich RH, Kodell RL, Morris SM, Casciano DA. Correlation between specific DNA-methylation products and mutation induction at the HGPRT locus in Chinese hamster ovary cells. *Mutat Res* 1983;110:171–180. [PubMed: 6865996]

206. Fortini P, Calcagnile A, Di Muccio A, Bignami M, Dogliotti E. Quantitative relationship between ethylated DNA bases and gene mutation at two loci in CHO cells. *Environ Mol Mutagen* 1993;21:154–159. [PubMed: 8383034]
207. Calleja F, Jansen JG, Vrieling H, Laval F, van Zeeland AA. Modulation of the toxic and mutagenic effects induced by methyl methanesulfonate in Chinese hamster ovary cells by overexpression of the rat N-alkylpurine-DNA glycosylase. *Mutat Res* 1999;425:185–194. [PubMed: 10216211]
208. Op het Veld CW, Jansen J, Zdzienicka MZ, Vrieling H, van Zeeland AA. Methyl methanesulfonate-induced hprt mutation spectra in the Chinese hamster cell line CHO9 and its xrcc1-deficient derivative EM-C11. *Mutat Res* 1998;398:83–92. [PubMed: 9626968]
209. Klungland A, Laake K, Hoff E, Seeberg E. Spectrum of mutations induced by methyl and ethyl methanesulfonate at the hprt locus of normal and tag expressing Chinese hamster fibroblasts. *Carcinogenesis* 1995;16:1281–1285. [PubMed: 7788844]
210. Loechler EL, Green CL, Essigmann JM. In vivo mutagenesis by O<sup>6</sup>-methylguanine built into a unique site in a viral genome. *Proc Natl Acad Sci U S A* 1984;81:6271–6275. [PubMed: 6093094]
211. Ellison KS, Dogliotti E, Connors TD, Basu AK, Essigmann JM. Site-specific mutagenesis by O<sup>6</sup>-alkylguanines located in the chromosomes of mammalian cells: influence of the mammalian O<sup>6</sup>-alkylguanine-DNA alkyltransferase. *Proc Natl Acad Sci U S A* 1989;86:8620–8624. [PubMed: 2813414]
212. Nivard MJM, Czene K, Segerback D, Vogel EW. Mutagenic activity of ethylene oxide and propylene oxide under XPG proficient and deficient conditions in relation to N-7-(2-hydroxyalkyl)guanine levels in *Drosophila*. *Mutat Res* 2003;529:95–107. [PubMed: 12943923]
213. Zhang S, Glickman BW, de Boer JG. Spontaneous mutation of the lacI transgene in rodents: absence of species, strain, and insertion-site influence. *Environ Mol Mutagen* 2001;37:141–146. [PubMed: 11246220]
214. Vergnes JS, Pritts IM. Effects of ethylene on micronucleus formation in the bone marrow of rats and mice following four weeks of inhalation exposure. *Mutat Res* 1994;324:87–91. [PubMed: 7517513]
215. Rios-Blanco MN, Faller TH, Nakamura J, Kessler W, Kreuzer PE, Ranasinghe A, Filser JG, Swenberg JA. Quantitation of DNA and hemoglobin adducts and apurinic/apyrimidinic sites in tissues of F344 rats exposed to propylene oxide by inhalation. *Carcinogenesis* 2000;21:2011–2018. [PubMed: 11062162]
216. O'Brien PJ, Ellenberger T. Dissecting the broad substrate specificity of human 3-methyladenine-DNA glycosylase. *J Biol Chem* 2004;279:9750–9757. [PubMed: 14688248]
217. O'Brien PJ, Ellenberger T. The *Escherichia coli* 3-methyladenine DNA glycosylase AlkA has a remarkably versatile active site. *J Biol Chem* 2004;279:26876–26884. [PubMed: 15126496]
218. Wyatt MD, Pittman DL. Methylating agents and DNA repair responses: Methylated bases and sources of strand breaks. *Chem Res Toxicol* 2006;19:1580–1594. [PubMed: 17173371]
219. McCarthy TV, Karran P, Lindahl T. Inducible repair of O-alkylated DNA pyrimidines in *Escherichia coli*. *EMBO J* 1984;3:545–550. [PubMed: 6370685]
220. Bjelland S, Bjoras M, Seeberg E. Excision of 3-methylguanine from alkylated DNA by 3-methyladenine DNA glycosylase I of *Escherichia coli*. *Nucleic Acids Res* 1993;21:2045–2049. [PubMed: 8502545]
221. Bjelland S, Birkeland NK, Benneche T, Volden G, Seeberg E. DNA glycosylase activities for thymine residues oxidized in the methyl group are functions of the AlkA enzyme in *Escherichia coli*. *J Biol Chem* 1994;269:30489–30495. [PubMed: 7982966]
222. Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. *Science* 2001;291:1284–1289. [PubMed: 11181991]
223. Wyatt MD, Allan JM, Lau AY, Ellenberger TE, Samson LD. 3-methyladenine DNA glycosylases: structure, function, and biological importance. *Bioessays* 1999;21:668–676. [PubMed: 10440863]
224. Simonelli V, Narciso L, Dogliotti E, Fortini P. Base excision repair intermediates are mutagenic in mammalian cells. *Nucleic Acids Res* 2005;33:4404–4411. [PubMed: 16077026]
225. Shane BS, Smith-Dunn DL, de Boer JG, Glickman BW, Cunningham ML. Mutant frequencies and mutation spectra of dimethylnitrosamine (DMN) at the lacI and cII loci in the livers of Big Blue transgenic mice. *Mutat Res* 2000;452:197–210. [PubMed: 11024479]

226. Wang X, Suzuki T, Itoh T, Honma M, Nishikawa A, Furukawa F, Takahashi M, Hayashi M, Kato T, Sofuni T. Specific mutational spectrum of dimethylnitrosamine in the lacI transgene of Big Blue C57BL/6 mice. *Mutagenesis* 1998;13:625–630. [PubMed: 9862195]
227. Souliotis VL, van Delft JH, Steenwinkel MJ, Baan RA, Kyrtopoulos SA. DNA adducts, mutant frequencies and mutation spectra in lambda lacZ transgenic mice treated with N-nitrosodimethylamine. *Carcinogenesis* 1998;19:731–739. [PubMed: 9635857]
228. Delker DA, Geter DR, Kleinert KM, Gollapudi BB. Frequency and spectrum of lacI mutations in the liver of Big Blue mice following the administration of genotoxic carcinogens singly and in series. *Int J Toxicol* 2008;27:35–42. [PubMed: 18293211]
229. Walker VE, Skopek TR. A mouse model for the study of in vivo mutational spectra: sequence specificity of ethylene oxide at the hprt locus. *Mutat Res* 1993;288:151–162. [PubMed: 7686258]
230. Recio L, Steen AM, Pluta LJ, Meyer KG, Saranko CJ. Mutational spectrum of 1,3-butadiene and metabolites 1,2-epoxybutene and 1,2,3,4-diepoxybutane to assess mutagenic mechanisms. *Chem Biol Interact* 2001;135-136:325–341. [PubMed: 11397399]
231. Lee DH, Kin TH, Lee SY, Kim HJ, Rhee SK, Yoon B, Pfeifer GP, Lee CS. Mutations induced by 1,3-butadiene metabolites, butadiene diolepoxide, and 1,2,3,4-diepoxybutane at the Hprt locus in CHO-K1 cells. *Mol Cells* 2002;14:411–419. [PubMed: 12521305]
232. Recio L, Pluta LJ, Meyer KG. The in vivo mutagenicity and mutational spectrum at the lacI transgene recovered from the spleens of B6C3F1 lacI transgenic mice following a 4-week inhalation exposure to 1,3-butadiene. *Mutat Res* 1998;401:99–110. [PubMed: 9639685]
233. Townsend L, Robins RK. Ring cleavage of purine nucleosides to yield possible biogenetic precursors of pteridines and riboflavin. *J Am Chem Soc* 1963;85:242–243.
234. Chetsanga CJ, Bearie B, Makaroff C. Alkaline opening of imidazole ring of 7-methylguanosine. 1. Analysis of the resulting pyrimidine derivatives. *Chem Biol Interact* 1982;41:217–233. [PubMed: 7049418]
235. Chetsanga CJ, Makaroff C. Alkaline opening of imidazole ring of 7-methylguanosine. 2. Further studies on reaction mechanisms and products. *Chem Biol Interact* 1982;41:235–249. [PubMed: 7105252]
236. Chetsanga CJ, Polidori G, Mainwaring M. Analysis and excision of ring-opened phosphoramidate mustard-deoxyguanine adducts in DNA. *Cancer Res* 1982;42:2616–2621. [PubMed: 7083154]
237. Box HC, Lilga KT, Potienko G. <sup>13</sup>C nuclear magnetic resonance studies of radiation damage: radiation-induced degradation of glycine. *Proc Natl Acad Sci U S A* 1977;74:2394–2396. [PubMed: 267933]
238. Darzynkiewicz E, Labadi I, Haber D, Burger K, Lonnberg H. 7-Methylguanine nucleotides and their structural analogues; protolytic equilibria, complexing with magnesium (II) ion and kinetics for alkaline opening of the imidazole ring. *Acta Chem Scand B* 1988;42:86–92. [PubMed: 3376659]
239. Griffin BE, Haines JA, Reese CB. The methylation of adenylyl-(3'-5')-uridine and uridylyl-(3'-5')-adenosine with diazomethane. *Biochim Biophys Acta* 1967;142:536–538. [PubMed: 6054275]
240. Wang JS, Groopman JD. DNA damage by mycotoxins. *Mutat Res* 1999;424:167–181. [PubMed: 10064859]
241. Tudek B. Imidazole ring-opened DNA purines and their biological significance. *J Biochem Mol Biol* 2003;36:12–19. [PubMed: 12542970]
242. Mao H, Deng Z, Wang F, Harris TM, Stone MP. An intercalated and thermally stable FAPY adduct of aflatoxin B1 in a DNA duplex: structural refinement from 1H NMR. *Biochemistry* 1998;37:4374–4387. [PubMed: 9521757]
243. Humphreys WG, Guengerich FP. Structure of formamidopyrimidine adducts as determined by NMR using specifically <sup>15</sup>N-labeled guanosine. *Chem Res Toxicol* 1991;4:632–636. [PubMed: 1807445]
244. Kadlubar FF, Beranek DT, Weis CC, Evans FE, Cox R, Irving CC. Characterization of the purine ring-opened 7-methylguanine and its persistence in rat bladder epithelial DNA after treatment with the carcinogen N-methylnitrosourea. *Carcinogenesis* 1984;5:587–592. [PubMed: 6722978]
245. Beranek DT, Weis CC, Evans FE, Chetsanga CJ, Kadlubar FF. Identification of N5-methyl-N5-formyl-2,5,6-triamino-4-hydroxypyrimidine as a major adduct in rat liver DNA after treatment with the carcinogens, N,N-dimethylnitrosamine or 1,2-dimethylhydrazine. *Biochem Biophys Res Commun* 1983;110:625–631. [PubMed: 6838542]

246. Busby, WF.; Wogan, GN. Aflatoxins. In: Searle, C., editor. Chemical Carcinogenesis. Am Chem Soc; Washington, DC: 1984. p. 945-1136.
247. Croy RG, Essigmann JM, Reinhold VN, Wogan GN. Identification of the principal aflatoxin B1-DNA adduct formed in vivo in rat liver. Proc Natl Acad Sci U S A 1978;75:1745-1749. [PubMed: 273905]
248. Lin JK, Miller JA, Miller EC. 2,3-Dihydro-2-(guan-7-yl)-3-hydroxy-aflatoxin B1, a major acid hydrolysis product of aflatoxin B1-DNA or -ribosomal RNA adducts formed in hepatic microsome-mediated reactions and in rat liver in vivo. Cancer Res 1977;37:4430-4438. [PubMed: 922734]
249. Croy RG, Wogan GN. Quantitative comparison of covalent aflatoxin-DNA adducts formed in rat and mouse livers and kidneys. J Natl Cancer Inst 1981;66:761-768. [PubMed: 6939922]
250. Croy RG, Wogan GN. Temporal patterns of covalent DNA adducts in rat liver after single and multiple doses of aflatoxin B1. Cancer Res 1981;41:197-203. [PubMed: 7448760]
251. Groopman JD, Croy RG, Wogan GN. In vitro reactions of aflatoxin B1-adducted DNA. Proc Natl Acad Sci U S A 1981;78:5445-5449. [PubMed: 6795633]
252. Martin CN, Garner RC. Aflatoxin B-oxide generated by chemical or enzymic oxidation of aflatoxin B1 causes guanine substitution in nucleic acids. Nature 1977;267:863-865. [PubMed: 895848]
253. Gopalakrishnan S, Harris TM, Stone MP. Intercalation of aflatoxin B1 in two oligodeoxynucleotide adducts: comparative 1H NMR analysis of d(ATCAFBGAT), d(ATCGAT) and d(ATAFBGCAT) 2. Biochemistry 1990;29:10438-10448. [PubMed: 2125491]
254. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427-428. [PubMed: 1849234]
255. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991;350:429-431. [PubMed: 1672732]
256. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-532. [PubMed: 2841597]
257. Bos JL, Fearon ER, Hamilton SR, Verlaan-de VM, van Boom JH, van der Eb AJ, Vogelstein B. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987;327:293-297. [PubMed: 3587348]
258. McMahon G, Hanson L, Lee JJ, Wogan GN. Identification of an activated c-Ki-ras oncogene in rat liver tumors induced by aflatoxin B1. PNAS 1986;83:9418-9422. [PubMed: 3099282]
259. Smela ME, Hamm ML, Henderson PT, Harris CM, Harris TM, Essigmann JM. The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. Proc Natl Acad Sci U S A 2002;99:6655-6660. [PubMed: 12011430]
260. Bailey EA, Iyer RS, Stone MP, Harris TM, Essigmann JM. Mutational properties of the primary aflatoxin B1-DNA adduct. PNAS 1996;93:1535-1539. [PubMed: 8643667]
261. Groopman JD. Do aflatoxin-DNA adduct measurements in humans provide accurate data for cancer risk assessment? IARC Sci Publ 1988;55-62. [PubMed: 3143672]
262. Groopman JD, Cain LG, Kensler TW. Aflatoxin exposure in human populations: measurements and relationship to cancer. Crit Rev Toxicol 1988;19:113-145. [PubMed: 3069332]
263. Ezaz-Nikpay K, Verdine GL. The effects of N7-methylguanine on duplex DNA structure. Chem Biol 1994;1:235-240. [PubMed: 9383396]
264. Lee S, Bowman BR, Ueno Y, Wang S, Verdine GL. Synthesis and structure of duplex DNA containing the genotoxic nucleobase lesion N7-methylguanine. J Am Chem Soc 2008;130:11570-11571. [PubMed: 18686953]
265. O'Connor TR, Boiteux S, Laval J. Ring-opened 7-methylguanine residues in DNA are a block to in vitro DNA synthesis. Nucl Acids Res 1988;16:5879-5894. [PubMed: 3399381]
266. Boiteux S, Laval J. Imidazole open ring 7-methylguanine: an inhibitor of DNA synthesis. Biochem Biophys Res Commun 1983;110:552-558. [PubMed: 6340667]
267. Bolt HM, Foth H, Hengstler JG, Degen GH. Carcinogenicity categorization of chemicals-new aspects to be considered in a European perspective. Toxicol Lett 2004;151:29-41. [PubMed: 15177638]

268. Gocke E, Müller L. In vivo studies in the mouse to define a threshold for genotoxicity of EMS. *Muta Res.* 2009
269. Segerback D, Calleman CJ, Schroeder JL, Costa LG, Faustman EM. Formation of N-7-(2-carbamoyl-2-hydroxyethyl)guanine in DNA of the mouse and the rat following intraperitoneal administration of [<sup>14</sup>C]acrylamide. *Carcinogenesis* 1995;16:1161–1165. [PubMed: 7767980]
270. Plna K, Nilsson R, Koskinen M, Segerback D. <sup>32</sup>P-postlabelling of propylene oxide 1-and N-6-substituted adenine and 3-substituted cytosine/uracil: formation and persistence in vitro and in vivo. *Carcinogenesis* 1999;20:2025–2032. [PubMed: 10506120]
271. Plna K, Segerback D, Schweda EK. DNA adduct formation by allyl glycidyl ether. *Carcinogenesis* 1996;17:1465–1471. [PubMed: 8706250]
272. Selzer RR, Elfarra AA. In vitro reactions of butadiene monoxide with single- and double-stranded DNA: characterization and quantitation of several purine and pyrimidine adducts. *Carcinogenesis* 1999;20:285–292. [PubMed: 10069466]
273. Tretyakova NY, Chiang SY, Walker VE, Swenberg JA. Quantitative analysis of 1,3-butadiene-induced DNA adducts in vivo and in vitro using liquid chromatography electrospray ionization tandem mass spectrometry. *J Mass Spectrom* 1998;33:363–376. [PubMed: 9597770]
274. Montesano R. Alkylation of DNA and tissue specificity in nitrosamine carcinogenesis. *J Supramol Struct Cell Biochem* 1981;17:259–273. [PubMed: 7328674]
275. Beranek DT, Weis CC, Swenson DH. A comprehensive quantitative analysis of methylated and ethylated DNA using high pressure liquid chromatography. *Carcinogenesis* 1980;1:595–606. [PubMed: 11219835]
276. Shields PG, Povey AC, Wilson VL, Weston A, Harris CC. Combined high-performance liquid chromatography/<sup>32</sup>P-postlabeling assay of N7-methyldeoxyguanosine. *Cancer Res* 1990;50:6580–6584. [PubMed: 2208119]
277. Petruzzelli S, Tavanti LM, Celi A, Giuntini C. Detection of N7-methyldeoxyguanosine adducts in human pulmonary alveolar cells. *Am J Respir Cell Mol Biol* 1996;15:216–223. [PubMed: 8703477]
278. Blomeke B, Greenblatt MJ, Doan VD, Bowman ED, Murphy SE, Chen CC, Kato S, Shields PG. Distribution of 7-alkyl-2'-deoxyguanosine adduct levels in human lung. *Carcinogenesis* 1996;17:741–748. [PubMed: 8625485]
279. Chen L, Wang M, Villalta PW, Hecht SS. Liquid chromatography-electrospray ionization tandem mass spectrometry analysis of 7-ethylguanine in human liver DNA. *Chem Res Toxicol.* 2007
280. Van Delft JHM, Van Winden MJM, Van Den Ende AMC, Baan RA. Determining N7-Alkylguanine Adducts by Immunochemical Methods and HPLC with Electrochemical Detection: Applications in Animal Studies and in Monitoring Human Exposure to Alkylating Agents. *Environ Health Perspect* 1993;99:25–32. [PubMed: 8319636]
281. Bodell WJ, Giannini DD, Hassenbusch S, Levin VA. Levels of N7-(2-hydroxyethyl)guanine as a molecular dosimeter of drug delivery to human brain tumors. *Neuro Oncol* 2001;3:241–245. [PubMed: 11584893]
282. Khan SA, Carmichael PL, Taylor-Robinson SD, Habib N, Thomas HC. DNA adducts, detected by <sup>32</sup>P postlabelling, in human cholangiocarcinoma. *Gut* 2003;52:586–591. [PubMed: 12631674]
283. Doak SH, Jenkins GJS, Johnson GE, Quick E, Parry EM, Parry JM. Mechanistic Influences for Mutation Induction Curves after Exposure to DNA-Reactive Carcinogens. *Cancer Res* 2007;67:3904–3911. [PubMed: 17440105]
284. Chiang SY, Huang TH, Uang SN, Wu HD, Wei YC, Lin HY, Swenberg JA, Wu KY. Analysis of 7-methylguanine using isotope dilution and gas chromatography/electron-capture negative chemical ionization mass spectrometry. *Rapid Commun Mass Spectrom* 2005;19:1915–1920. [PubMed: 15954176]
285. Frei JV, Swenson DH, Warren W, Lawley PD. Alkylation of deoxyribonucleic acid *in vivo* in various organs of C57BL mice by the carcinogens N-methyl-N-nitrosourea, N-ethyl-N-nitrosourea and ethyl methanesulfonate in relation to induction of thymic lymphoma. *Biochemical J* 1978;174:1031–1044.
286. van Zeeland AA, Mohn GR, Neuhauser-Klaus A, Ehling UH. Quantitative comparison of genetic effects of ethylating agents on the basis of DNA adduct formation. Use of O6-ethylguanine as

- molecular dosimeter for extrapolation from cells in culture to the mouse. *Environ Health Perspect* 1985;62:163–169. [PubMed: 3910416]
287. Swenson DH, Petzold GL, Harbach PR. The binding of 1-(2-hydroxyethyl)-1-nitrosourea to DNA in vitro and to DNA of thymus and marrow in C57BL mice in vivo. *Cancer Lett* 1986;33:75–81. [PubMed: 3768862]
288. Segerback D, Osterman-Golkar S, Molholt B, Nilsson R. In vivo tissue dosimetry as a basis for cross-species extrapolation in cancer risk assessment of propylene oxide. *Regul Toxicol Pharmacol* 1994;20:1–14. [PubMed: 7838987]
289. Vodicka PE, Linhart I, Novak J, Koskinen M, Vodickova L, Hemminki K. 7-Alkylguanine adduct levels in urine, lungs and liver of mice exposed to styrene by inhalation. *Toxicol Appl Pharmacol* 2006;210:1–8. [PubMed: 15949832]
290. Pauwels W, Vodiceka P, Severi M, Plna K, Veulemans H, Hemminki K. Adduct formation on DNA and haemoglobin in mice intraperitoneally administered with styrene. *Carcinogenesis* 1996;17:2673–2680. [PubMed: 9006105]
291. La DK, Schoonhoven R, Ito N, Swenberg JA. The effects of exposure route on DNA adduct formation and cellular proliferation by 1,2,3-trichloropropane. *Toxicol Appl Pharmacol* 1996;140:108–114. [PubMed: 8806876]
292. Zeiger E, Recio L, Fennell TR, Haseman JK, Snyder RW, Friedman M. Investigation of the low-dose response in the in vivo induction of micronuclei and adducts by acrylamide. *Toxicol Sci* 2009;107:247–257. [PubMed: 18931380]
293. Ghanayem BI, McDaniel LP, Churchwell MI, Twaddle NC, Snyder R, Fennell TR, Doerge DR. Role of CYP2E1 in the epoxidation of acrylamide to glycidamide and formation of DNA and hemoglobin adducts. *Toxicol Sci* 2005;88:311–318. [PubMed: 16141435]
294. Swenberg, JA.; Bedell, MA. Banbury Report 113: Indicators of Genotoxic Exposure. Cold Spring Harbor Laboratory; Cold Spring Harbor: 1982. Cell-specific DNA alkylation and repair: Application of new fluorometric techniques to detect adducts; p. 205-220.
295. Lewis JG, Swenberg JA. Effect of 1,2-dimethylhydrazine and diethylnitrosamine on cell replication and unscheduled DNA synthesis in target and nontarget cell populations in rat liver following chronic administration. *Cancer Res* 1982;42:89–92. [PubMed: 7053871]
296. Lewis JG, Swenberg JA. The kinetics of DNA alkylation, repair and replication in hepatocytes, Kupffer cells, and sinusoidal endothelial cells in rat liver during continuous exposure to 1,2-dimethylhydrazine. *Carcinogenesis* 1983;4:529–536. [PubMed: 6189632]
297. Brink A, Schulz B, Stopper H, Lutz WK. Biological significance of DNA adducts investigated by simultaneous analysis of different endpoints of genotoxicity in L5178Y mouse lymphoma cells treated with methyl methanesulfonate. *Mutat Res* 2007;625:94–101. [PubMed: 17586535]
298. Souliotis VL, Henneman JR, Reed CD, Chhabra SK, Diwan BA, Anderson LM, Kyrtopoulos SA. DNA adducts and liver DNA replication in rats during chronic exposure to N-nitrosodimethylamine (NDMA) and their relationships to the dose-dependence of NDMA hepatocarcinogenesis. *Mutat Res* 2002;500:75–87. [PubMed: 11890936]
299. Koepke SR, Kroeger-Koepke MB, Bosan W, Thomas BJ, Alvord WG, Michejda CJ. Alkylation of DNA in rats by N-nitrosomethyl-(2-hydroxyethyl)amine: dose response and persistence of the alkylated lesions in vivo. *Cancer Res* 1988;48:1537–1542. [PubMed: 3345527]
300. Swann PF, Pegg AE, Hawks A, Farber E, Magee PN. Evidence for ethylation of rat liver deoxyribonucleic acid after administration of ethionine. *Biochem J* 1971;123:175–181. [PubMed: 5127333]
301. Swann PF, Magee PN. Nitrosamine-induced carcinogenesis. The alkylation of N-7 of guanine of nucleic acids of the rat by diethylnitrosamine, N-ethyl-N-nitrosourea and ethyl methanesulphonate. *Biochem J* 1971;125:841–847. [PubMed: 5145908]
302. Netto LE, RamaKrishna NV, Kolar C, Cavalieri EL, Rogan EG, Lawson TA, Augusto O. Identification of C8-methylguanine in the hydrolysates of DNA from rats administered 1,2-dimethylhydrazine. Evidence for in vivo DNA alkylation by methyl radicals. *J Biol Chem* 1992;267:21524–21527. [PubMed: 1400464]




303. Papanikolaou A, Shank RC, Delker DA, Povey A, Cooper DP, Rosenberg DW. Initial levels of azoxymethane-induced DNA methyl adducts are not predictive of tumor susceptibility in inbred mice. *Toxicol Appl Pharmacol* 1998;150:196–203. [PubMed: 9630469]
304. Fedtke N, Walker VE, Swenberg JA. Determination of 7-(2-oxoethyl)guanine and N<sup>2,3</sup>-ethenoguanine in DNA hydrolysates by HPLC. *Arch Toxicol* 1989;214–218. [PubMed: 2764708]
305. Maniere I, Godard T, Doerge DR, Churchwell MI, Guffroy M, Laurentie M, Poul JM. DNA damage and DNA adduct formation in rat tissues following oral administration of acrylamide. *Mutat Res* 2005;580:119–129. [PubMed: 15668114]

## Abbreviations


<b>AFB<sub>1</sub>-FAPy</b>	5- <i>N</i> -(9-hydroxyafatoxin)-2,6,-diamino-4-hydroxyformamidopyrimidine
<b>Alkyl-FAPy</b>	5- <i>N</i> -alkyl-2,6,-diamino-4-hydroxyformamidopyrimidine
<b>AGE</b>	allyl glycidyl ether
<b>AP-sites</b>	apurinic sites
<b>BER</b>	base excision repair
<b>bisN7-Gua-BD-diol</b>	1,4-bis(guan-7-yl)-2,3-butanediol
<b>DEB</b>	1,2;3,4-diepoxybutane
<b>DEN</b>	diethylnitrosamine
<b>DES</b>	diethylsulfate
<b>EB</b>	1,2-epoxy-3-butene
<b>EB-diol</b>	1,2-epoxy-3,4-butanediol
<b>ECH</b>	epichlorohydrin
<b>EMS</b>	ethylmethanesulfonate
<b>ENU</b>	ethylnitrosourea
<b>EO</b>	ethylene oxide
<b>ET</b>	ethylene

<b>HENU</b>	1-(2-hydroxyethyl)-1-nitrosourea
<b>HPLC-ECD</b>	High pressure liquid chromatography with electro chemical detection
<b>ISB</b>	Immunoslot blot
<b>KC</b>	Kupffer cells
<b>LC-MS/MS</b>	Liquid chromatography tandem mass spectrometry
<b>Me-FAPy</b>	5- <i>N</i> -methyl-2,6,-diamino-4-hydroxyformamidopyrimidine
<b>MF</b>	mutation frequency
<b>MMS</b>	methylmethanesulfonate
<b>MN</b>	micronucleus
<b>MNU</b>	<i>N</i> -methyl- <i>N</i> -nitrosourea
<b><i>N</i>7-AFB<sub>1</sub>-Gua</b>	<i>N</i> 7-(9-hydroxyafatoxin)-guanine
<b><i>N</i>7-Et-Gua</b>	<i>N</i> 7-ethyl-guanine
<b><i>N</i>7-Gua-<i>N</i>1-Ade-BD-diol</b>	1-(guan-7-yl)-4-(aden-1-yl)-2,3-butanediol
<b><i>N</i>7-HB-Gua</b>	<i>N</i> 7-hydroxybutenly-guanine
<b><i>N</i>7-HE-Gua</b>	<i>N</i> 7-hydroxyethyl-guanine
<b><i>N</i>7-HMGSH-Gua</b>	S-[1-(hydroxymethyl)-2-( <i>N</i> 7-guanyl)ethyl]-glutathione
<b><i>N</i>7-HP-Gua</b>	<i>N</i> 7-hydroxypropyl-guanine
<b><i>N</i>7-Me-Gua</b>	<i>N</i> 7-methyl-guanine
<b><i>N</i>7-THB-Gua</b>	<i>N</i> 7-trihydroxybutanly-guanine
<b>nnt</b>	normal nucleotides


<b>NPC</b>	non-parenchymal cells
<b>NS</b>	non smokers
<b><i>O</i><sup>2</sup>-Et-Thy</b>	<i>O</i> <sup>2</sup> -ethyl-thymidine
<b><i>O</i><sup>4</sup>-Et-Thy</b>	<i>O</i> <sup>4</sup> -ethyl-thymidine
<b><i>O</i><sup>6</sup>-Et-Gua</b>	<i>O</i> <sup>6</sup> -ethyl-guanine
<b><i>O</i><sup>6</sup>-Me-Gua</b>	<i>O</i> <sup>6</sup> -methyl-guanine
<b><i>O</i><sup>6</sup>MT</b>	<i>O</i> <sup>6</sup> -methylguanine DNA-methyltransferase
<b><sup>32</sup>P</b>	<sup>32</sup> P-postlabeling
<b><sup>32</sup>P-AEC</b>	<sup>32</sup> P-postlabeling anion exchange chromatography
<b>PO</b>	propylene oxide
<b>S</b>	smokers
<b>SDMH</b>	1,2-dimethylhydrazine
<b>SEC</b>	sinusoidal endothelia cells
<b>SO</b>	styrene oxide
<b>SSB</b>	single strand breaks
<b>TCP</b>	1,2,3-Trichloropropane
<b>THB-Val</b>	trihydroxybutanlyl-valine




**Figure 1.** Guanine and adenine methylation by MNU relative to *N7*-Me-Gua formation (100%).



**Figure 2.** Formation of N7-guanine adducts from diazonium ion metabolites of NNK. NNK is metabolized by P450-catalyzed  $\alpha$ -hydroxylation, producing hydroxymethyl NNK (2) and  $\alpha$ -methylenehydroxy NNK (3), which spontaneously decompose to their corresponding diazonium ions (4,5), and keto aldehyde and formaldehyde, respectively. The highly reactive diazonium ions (4,5) subsequently form DNA adducts including N7-guanine adducts [82].


**Figure 3.**

Example of olefin metabolism and formation of *N7*-guanine adducts illustrated on BD. BD is metabolized by P450s to several epoxides that form DNA adducts including *N7*-guanine adducts. Shown are *N7*-HB-Gua, bis*N7*-Gua-BD-diol and THB-Gua as representative *N7*-guanine adducts formed from EB, DEB and EB-diol, respectively.



**Figure 4.**


Comparison of the dose-responses for formation of *N7*-hydroxyalkyl-Gua adducts following repeated exposure to the olefins ethylene (A) and propylene (C), and their epoxy metabolites EO (B) and PO (D), respectively. Formation of *N7*-guanine adducts is much more efficient for the epoxide metabolite compared to the parent olefin. Data are from rat lung after 20 days inhalation exposures to olefins and their epoxides [33,127,133,149].



**Figure 5.**

Determination of the number of *N*7-Me-Gua adducts present with an imbalance in BER. NAD (P)H values for CHO AA8 cells were plotted against the corresponding cumulative dose (the product of mM MMS and exposure duration). The X value corresponding to the intersection of the resulting linear regression line and  $y = 100$  (*i.e.*, 100% NAD(P)H relative to controls) was determined to be the start of an imbalance in BER. In the case of AA8 cells, exposure to 1.96 mM MMS for 1 hr initiated the imbalance of BER (unpublished results from Pachkowski *et al*).





**Figure 6.** Formation of endogenous and exogenous *N7*-Me-Gua in AHH-1 cells exposed to [ $^{13}\text{C}_2$ ] MMS for 24 h (Modified from Swenberg et al [27]). Exogenous *N7*-Me-Gua adducts were distinguished from endogenous *N7*-Me-Gua base on mass differences due to stable isotope labeled [ $^{13}\text{C}_2$ ] MMS used for cell treatment. Adduct amounts were compared to mutation frequency in HPRT gene as reported by Doak et al. [283].

Table 1

## Relative reactivity [%] of nucleophilic sites in DNA

Chemical	N7-Gua	O <sup>6</sup> -Gua	N <sup>2</sup> -Gua	N3-Ade	N1Ade/N <sup>6</sup> Ade	N3-Cyt	N <sup>4</sup> -Cyt	Reference
<b>PO</b>	100	0.5	-	4,4/10	3.5	2	-	[269,270]
<b>EO</b>	100	-	-	10	10	1	-	[125]
<b>AGE</b>	100	-	-	11	14	6	-	[271]
<b>ECH</b>	100	-	-		9	4	-	[125]
<b>SO</b>	100		4.5	10	16	5	2	[125]
<b>EB</b>	100			15	25	1.5		[153,272,273]
<b>MNU</b>	100	10	-	12	1.2	0.8	-	[274,275]
<b>MMS</b>	100	3.7		12	2	-	-	[274,275]
<b>ENU</b>	100	66		30	2	2	-	[274,275]
<b>EMS</b>	100	3.4		7	3	0.6		[274,275]

AGE; allyl glycidyl ether, ECH; epichlorohydrin

**Table 2**  
**Dose response of some *N7*-guanine adducts in rats exposed to representative olefins in rat liver**

Compound	Dose response Max adduct (adducts / 10 <sup>7</sup> )	Adduct	Reference
Ethylene	Saturates at ~7 adduct/ 10 <sup>7</sup> nnt	<i>N7</i> -HE-Gua	[33]
Ethylene oxide	Linear up to 463.8 adducts / 10 <sup>7</sup> nnt	<i>N7</i> -HE-Gua	[129,133]
Propylene	Saturates at 6.5 adducts / 10 <sup>7</sup> nnt	<i>N7</i> -HP-Gua	[149]
Propylene oxide	Linear up to 915 adducts / 10 <sup>7</sup> nnt	<i>N7</i> -HP-Gua	[127]
Butadiene	Saturates at 23 adducts / 10 <sup>7</sup> nnt	<i>N7</i> -THB-Gua	[68]

**Table 3**  
**Amounts of N7-guanine adducts in human DNA**

Adduct/ Tissue	Group	Method	N7-Gua adducts/10 <sup>7</sup> nnt (n)	Ref
<b>N7-Me-Gua</b>				
WBC	Age<50	<sup>32</sup> P-HPLC	1.0 ± 0.9 (14)	[188]
WBC	Age >80	<sup>32</sup> P-HPLC	0.8 ± 0.4 (20)	[188]
WBC	NS	<sup>32</sup> P-HPLC	2.5	[191]
WBC	NS	<sup>32</sup> P-AEC	2.3 (6)	[190]
WBC	S	<sup>32</sup> P-AEC	11.5 (11)	[190]
WBC	NS	<sup>32</sup> P-AEC	3.4 (10)	[189]
WBC	S	<sup>32</sup> P-AEC	6.9 (10)	[189]
Granulocytes	NS	<sup>32</sup> P-AEC	2.8 (10)	[189]
Granulocytes	S	<sup>32</sup> P-AEC	4.7 (10)	[189]
Lymphocytes	NS	<sup>32</sup> P-AEC	13.5 (10)	[189]
Lymphocytes	S	<sup>32</sup> P-AEC	23.6 (10)	[189]
Lymphocytes		<sup>32</sup> P-HPLC	6.94 (5)	[142]
Lung	Lung cancer patients	<sup>32</sup> P-HPLC	6.3 ± 1.9 (5)	[146]
Bronchial tissue	Lung cancer patients	<sup>32</sup> P-HPLC	6.1 ± 1.5 (5)	[146]
Lymphocytes	Lung cancer patients	<sup>32</sup> P-HPLC	3.3 ± 0.9 (5)	[146]
Lung		<sup>32</sup> P-HPLC	39.4 (5)	[276]
Lung		<sup>32</sup> P-HPLC	2.7 (10)	[142]
Bronchial tissue	NS	<sup>32</sup> P-HPLC	4.7 (6)	[190]
Bronchial tissue	S	<sup>32</sup> P-HPLC	17.3 (11)	[190]
Cervical cytology	NS	ISB	0.82 <sup>b</sup> (17)	[187]
Cervical cytology	S	ISB	2.5 <sup>b</sup> (22)	[187]
lymphocytes	NS	HPLC-ECD	4.5 (8)	[193]
lymphocytes	S	HPLC-ECD	3.9 (14)	[193]
Colon mucosa		ISB & <sup>32</sup> P	1.7 <sup>b</sup> (6)	[192]
Rectal mucosa		ISB & <sup>32</sup> P	0.7 <sup>b</sup> (5)	[192]
Bronchial Lavage			11.9	[277]
Bronchial Lavage	Ex-smoker	<sup>32</sup> P-HPLC	9.99 ± 20.3 (10)	[195]
Bronchial Lavage	Ex-Smokers	<sup>32</sup> P-HPLC	5.59 ± 15.6 (28)	[195]
Bronchial Lavage	Never smokers	<sup>32</sup> P-HPLC	0.58 ± 0.5 (6)	[195]
Bladder	Tumor		0.1	[194]
			0.5	[194]
Lung		<sup>32</sup> P	2.5 (80)	[278]
Lung		<sup>32</sup> P-HPLC	2.74 (10)	[142]
Lung		<sup>32</sup> P	2.11 (90)	[142]
<b>N7-alkyl-Gua</b>				
Larynx tumor	NS	<sup>32</sup> P	11.3 23.2 (5)	[196]
Larynx tumor	FS	<sup>32</sup> P	23.2 ± 24.1(34)	[196]
Larynx tumor	S	<sup>32</sup> P	61.8 ± 84.5 (5)	[196]
Larynx non-tumor	NS	<sup>32</sup> P	8.3 ± 6.0 (3)	[196]

Adduct/ Tissue	Group	Method	N7-Gua adducts/10 <sup>7</sup> nnt (n)	Ref
Larynx non-tumor	FS	<sup>32</sup> P	21.1 ± 18.7 (25)	[196]
Larynx non-tumor	S	<sup>32</sup> P	36.3 ± 20.2 (6)	[196]
<b>N7-Me-Gua N7-HE-Gua</b>				
WBC	NS	<sup>32</sup> P-HPLC	2.9 ± 0.9 (8)	[146]
WBC	S	<sup>32</sup> P-HPLC	3.9 ± 0.8 (11)	[146]
Lung	NS	<sup>32</sup> P-HPLC	4.0 [3.6, 4.4](2)	[146]
Lung	S	<sup>32</sup> P-HPLC	6.5 ± 2.2 (7)	[146]
N7-Et-Gua				
Liver			0.084(25)	[279]
Lymphocytes		<sup>32</sup> P-HPLC	1.0 (5)	[142]
Lung		<sup>32</sup> P-HPLC	1.46 (10)	[142]
Lung		<sup>32</sup> P	1.6 (75)	[278]
N7-HE-Gua				
WBC	Controls subjects	HPLC-UV	10.5 ± 4.8 <sup>a</sup> (5)	[141]
WBC		Immuno blot	0.65	[280]
WBC	S	Immuno blot	0.11	[280]
WBC	NS	Immuno blot	0.095	[280]
lymphocytes	Control subjects	GC-HRMS	4.85 ± 3.1 <sup>b</sup> (23)	[128]
Granulocytes	Hospital Workers	GC-MS	9.6 ± 5.8 (6)	[143]
Granulocytes	Non exposed			
Granulocytes	Hospital Workers	GC-MS	13.6 ± 3.9(38)	[143]
Granulocytes	<32 ppm-hr ET			
Granulocytes	Hospital Workers	GC-MS	22.7 ± 11.7 (20)	[143]
Granulocytes	>32 ppm-hr Et			
Lung	Lung cancer patients	<sup>32</sup> P-HPLC	0.8 ± 0.3 (5)	[146]
Bronchial tissue	Lung cancer patients	<sup>32</sup> P-HPLC	1.0 ± 0.8 (5)	[146]
Lymphocytes	Lung cancer patients	<sup>32</sup> P-HPLC	0.6 ± 0.2 (5)	[146]
N7-HOEt-Gua				
brain tissue	Non treated	HPLC-ECD	1.15 ± 0.63 (6) <sup>b</sup>	[281]
Brain tissues distal	DTI-015 treated	HPLC-ECD	1.6 (6) <sup>b</sup>	[281]
Brain tissues medial	DTI-015 treated	HPLC-ECD	5.1 (6) <sup>b</sup>	[281]
brain tissues adjacent	DTI-015 treated	HPLC-ECD	721 (6) <sup>b</sup>	[281]
RAL	Non cancer	<sup>32</sup> P	2.9 (0.6-11.5)	[282]
RAL	Cholangiocarcinoma	<sup>32</sup> P	7.2 (1.8-48.4)	[282]
RAL	Tumor adjacent	<sup>32</sup> P	8.6 (1.2-51.6)	[282]

<sup>a</sup> Adduct unit was converted using following calculation: 1 fmol/ μg DNA = 3.25 adducts/ 10<sup>7</sup> nnt

<sup>b</sup> Adduct unit was converted using following calculation: 1 pmol/ μmol Guanine = 1.95 adducts/ 10<sup>7</sup> nnt

NS; non smokers, S; smokers, ISB; Immunoslot blot, <sup>32</sup>P; <sup>32</sup>P-postlabeling, <sup>32</sup>P-AEC; <sup>32</sup>P-postlabeling anion exchange chromatography